Synthomer plc
Interim results for the six months ended 30 June
2024
Continued strategic and
operational progress
Six months ended 30
June
|
H1 2024
|
H1 2023
|
Change
|
Constant
currency1
|
|
£m
|
£m
|
%
|
%
|
Continuing
operations2
|
|
|
|
|
Revenue
|
1,051.1
|
1,047.2
|
+0.4%
|
+3.5%
|
Coatings
& Construction Solutions (CCS)
|
53.0
|
54.9
|
(3.5)%
|
(0.9)%
|
Adhesive
Solutions (AS)
|
21.9
|
15.6
|
+40.4%
|
+42.9%
|
Health
& Protection and Performance Materials (HPPM)
|
14.8
|
12.3
|
+20.3%
|
+24.4%
|
Corporate
|
(13.7)
|
(10.0)
|
|
|
EBITDA3
|
76.0
|
72.8
|
+4.4%
|
+7.6%
|
EBITDA
margin (%)
|
7.2%
|
7.0%
|
|
|
Underlying4 operating profit (EBIT)
|
29.0
|
25.1
|
+15.5%
|
+18.7%
|
Statutory
operating profit/(loss) (EBIT)
|
(2.2)
|
(7.1)
|
|
|
Results from continuing and
discontinued operations2
|
|
|
|
|
Underlying4 profit/(loss) before tax
|
2.5
|
(6.7)
|
|
|
Statutory
(loss)/profit before tax
|
(33.2)
|
16.7
|
|
|
Underlying4 EPS* (p)
|
1.3
|
(8.0)
|
|
|
Basic
EPS* (p)
|
(18.8)
|
(19.0)
|
|
|
Free Cash
Flow5
|
(31.2)
|
18.8
|
|
|
Net
debt6
|
560.6
|
795.8
|
|
|
* H1 2023
adjusted for 20 to 1 share consolidation and rights issue
adjustment factor of 2.715.
·
H1 trading in line with
expectations, with revenue, earnings and underlying EPS
progression
·
Activity levels continued to
incrementally improve in the period
− CCS
remained stable and resilient while AS and HPPM divisions recovered
some of the substantial volume declines experienced in 2023;
specialities across the Group continued to outperform base
products
− Activity
levels and capacity utilisation increasing, but still significantly
below pre-pandemic levels
− Revenue
+3.5% in constant currency despite pass-through of lower raw
material prices vs H1 2023
·
EBITDA and margin progress
principally from self-help actions
− Gross
profit improved, reflecting benefits of our speciality strategy and
higher capacity utilisation
− £13m
benefits from cost savings and reliability improvement programmes
in period, partially offset by previously-disclosed operating cost
increases
·
On track for positive Free
Cash Flow for full year; debt maturities extended
− Net debt
increased in period as expected, reflecting EC settlement and net
working capital movements (driven by seasonality and higher raw
material prices since the start of the period)
− Net
debt: EBITDA ratio of 4.7x well within covenant requirements; more
than £500m of committed liquidity
− €350m
bond refinancing completed, next major debt maturity in
2027
·
Strategic transformation
towards higher margin, more resilient speciality solutions
progressing well
−
Compounds divestment completed in April, further focusing
Group and reducing site complexity; other non-core divestments and
partnership opportunities progressing
−
Continuing to shift resource allocation towards areas of
greatest future opportunity
− Clear
evidence the Group is becoming more end-customer focused,
innovative and sustainability-led
·
Recent trading remains in
line with expectations; 2024 outlook reiterated
− Volumes
in a number of businesses continue to improve from historically low
levels, but no evidence of sustained end-market demand improvement
at this stage
− As
previously indicated, expect some earnings progress (on a
continuing Group basis) and to be at least modestly Free Cash Flow
positive in 2024, even absent broad-based macroeconomic demand
improvement
Commenting,
Synthomer CEO Michael Willome said:
"While we remain cautiously encouraged by
trading in some end markets since the start of the year, evidence
of a broad-based recovery in demand remains limited. Despite this,
we have made earnings progress by delivering on our cost and
operational efficiency programmes, and we continue to strengthen
our strategic positioning for the future by focusing on our
speciality businesses, creatively managing our resources and
enhancing our operating leverage."
A webcast
presentation for analysts and investors will take place at 10:00am
BST today, accessible via our website at
www.synthomer.com
or on
https://brrmedia.news/SYNT_IR_24.
This will also be available for playback after the
event.
Further information:
Investors: Faisal Tabbah, Vice
President Investor Relations
|
Tel: +44 (0) 1279 775 306
|
Media: Nick Hasell, FTI
Consulting
|
Tel: +44 (0) 203 727 1340
|
Notes
1. Constant currency revenue and profit
measures retranslate current year results using the prior year's
average exchange rates.
2. Laminates, Films and Coated Fabrics, North
America Paper and Carpet and the Compounds business, which combined
contributed revenue of £9.8m and EBITDA of £2.6m in H1 2024 (H1
2023: £56.2m and £1.7m respectively), are classed as discontinued
operations throughout this announcement.
3. Operating profit before depreciation,
amortisation and Special Items.
4. Underlying performance excludes Special
Items unless otherwise stated.
5 Free Cash Flow is defined as the movement
in net debt before financing activities, foreign exchange and the
cash impact of Special Items, asset disposals and business
combinations.
6. Cash and cash equivalents together with
short and long-term borrowings.
7. Operating Cash Flow is defined as Total
Group EBITDA plus/minus net working capital movement less capital
expenditure.
Legal Entity Identifier (LEI):
213800EHT3TI1KPQQJ56. Classification as per DTR 6 Annex 1R:
1.2.
Synthomer plc is a leading supplier
of high-performance, highly specialised polymers and ingredients
that play vital roles in key sectors such as coatings,
construction, adhesives, and health and protection - growing
markets that serve billions of end users worldwide. Headquartered
in London, UK and listed there since 1971, we employ c.4,200
employees across our five innovation centres of excellence and more
than 30 manufacturing sites across Europe, North America, Middle
East and Asia. With more than 6,000 blue-chip customers and £2.0bn
in continuing revenue in 2023, our business is built around three
divisions, serving customers in attractive end markets where demand
is driven by global megatrends including urbanisation, demographic
change, climate change and sustainability, and shifting economic
power. In Coatings & Construction Solutions, our specialist
polymers enhance the sustainability and performance of a wide range
of coatings and construction products. We serve customers in
applications including architectural and masonry coatings, mortar
modification, waterproofing and flooring, fibre bonding, and energy
solutions. In Adhesive Solutions our products help our customers
bond, modify and compatibilise surfaces and components for
applications including tapes and labels, packaging, hygiene, tyres
and plastic modification, improving permeability, strength,
elasticity, damping, dispersion and grip. In Health &
Protection and Performance Materials we are a world-leading
supplier of water-based polymers for medical gloves, and a major
European manufacturer of high-performance binders, foams and other
products serving customers in a range of end markets. Our purpose
is creating innovative and sustainable solutions for the benefit of
customers and society. Around 20% of our sales volumes are from new
and patent protected products. At our innovation centres of
excellence in the UK, China, Germany, Malaysia and Ohio, USA we
collaborate closely with our customers to develop new products and
enhance existing ones tailored to their needs, with an increasing
range of sustainability benefits. Our 2030 decarbonisation targets
have been approved by the Science Based Targets initiative as being
in line with what the latest climate science says is necessary to
meet the goals of the Paris Agreement, and since 2021 we have held
the London Stock Exchange Green Economy Mark, which recognises
green technology businesses making a significant contribution to a
more sustainable, low-carbon economy. Find us at
www.synthomer.com
or search for Synthomer on LinkedIn.
CHIEF EXECUTIVE OFFICER'S REVIEW
Trading in the first half of 2024 was in line
with expectations, with underlying earnings progress driven mainly
by our self-help activities as demand conditions in our end markets
have only incrementally improved during the period. While clear
evidence of a sustained recovery remains limited, we continue to
reposition the organisation to deliver our medium-term strategic
and financial ambitions as we aim to become a more focused, more
specialised and more global chemicals solutions
provider.
Earnings progress driven mainly by self-help
We are encouraged by the Group's progress, with
continuing Group revenue and EBITDA increasing by 3.5% and 7.6%
respectively in constant currency. Market conditions across the
Group were mixed, with a 10.7% increase in volume driven by a
recovery of some of the substantial declines experienced in 2023,
with our speciality businesses continuing to outperform base
products. Our focus remains on staying close to our customers in a
volatile market environment, while ensuring we are well-placed for
recovery.
In addition to some operating leverage gains,
our underlying financial performance benefitted from further
progress on our 'self-help' initiatives. As anticipated, these
actions to reduce cost and complexity, to improve site reliability
(especially of the acquired adhesive resins businesses), and to
optimise our procurement and production costs were partially offset
by some increases in other operating costs, mainly due to wage
inflation and normalisation of bonus accrual in the
year.
As our most speciality focused division,
Coatings & Construction
Solutions (CCS) has been the most resilient
over recent periods. Despite limited improvement in overall
activity levels in its end markets and a 2.1% revenue reduction in
constant currency, our ongoing focus on enhancing our speciality
offering for customers drove improved gross profitability, meaning
that, despite the higher operating costs previously flagged in the
period, the division was able to modestly increase EBITDA margin to
12.3% on the prior year period (H1 2023: 12.1%). CCS generated
£53.0m of EBITDA (H1 2023: £54.9m) in the seasonally more
significant half of the financial year, 0.9% lower than in H1 2023
in constant currency.
Our Adhesive Solutions (AS)
division has made good progress with its performance
improvement programme, delivering £8m in benefits during the period
through improving efficiency and reliability. Although still some
way short of our long-term ambitions, Divisional EBITDA was
substantially improved at £21.9m (H1 2023: £15.6m), an EBITDA
margin of 7.1% (H1 2023: 5.0%) for the period. Activity levels
improved in the period, with market share gains particularly in the
base products that had been under significant pressure from global
competitors during the second half of 2023. Volumes and especially
unit margins also improved in the speciality portion of AS'
portfolio (c.60% of divisional revenue) in the period.
Meanwhile, nitrile butadiene latex (NBR) volumes
in our Heath &
Protection and Performance Materials (HPPM)
division continued to improve from their post-pandemic lows,
underpinned by the hygiene growth megatrend for end-customer
medical glove use, albeit at what remain historically low unit
margins. In our Performance Materials portfolio, which includes a
number of businesses assessed as non-core to the wider Group
strategy, volumes also began to improve in the period. As a
predominantly base chemicals division, HPPM's gross profit is
highly sensitive to volumes. Divisional EBITDA increased to £14.8m
(H1 2023: £12.3m) and EBITDA margin improved to 4.7% compared with
the prior year period (H1 2023: 4.3%).
On track for positive Free Cash Flow for full year; debt
maturities extended
Net debt of £560.6m (H1 2023: £795.8m, FY 2023:
£499.7m) was in line with our expectations, partly reflecting
payment of the EC fine settlement amount of £39.1m in January as
previously described, partially offset by the £20.6m net cash
inflow from the Compounds divestment in April. Our Free Cash Flow
performance in the period was consistent with our expectations,
recognising that raw material prices and activity levels - and
hence net working capital - were all higher at the end of June 2024
than in December 2023 (in part due to seasonal variations). These
were partially offset by inflows from the receivables financing
facilities and active inventory management during the
period.
As a result, the Group's net debt: EBITDA for
the purposes of the leverage ratio covenant increased from 4.2x at
31 December 2023 to 4.7x at 30 June 2024, well within the required
covenant of not more than 6.0x.
Alongside our operational focus on cash, the
balance sheet has also been strengthened further. In April, we
successfully tendered for €370m of our bonds due 2025, reducing
gross debt and extending maturities by issuing €350m of bonds due
2029. Our next significant debt maturity is now in 2027.
Speciality solutions strategy progressing
well
We continue to deliver a number of initiatives
to support our strategic transformation towards higher margin, more
resilient speciality solutions business areas, with allocation of
our resources shifting towards our greatest opportunities for our
future value creation.
Portfolio management
In April we completed the divestment of our
non-core latex compounding business for an EV/standalone trailing
EBITDA multiple of 6x and a profit on disposal before the recycling
of translation reserves of £1.4m. The divestment included two
manufacturing sites in the Netherlands and one in Egypt. Together
with other site rationalisations and divestments, our site
footprint has reduced from 43 to 32 in two years.
We have a number of other non-core divestments
underway which continue to progress, including of our SBR business
for European paper and carpet markets. We also continue to explore
potential partnership opportunities which would allow us to
leverage our intellectual property, technology and manufacturing
expertise in certain product areas to grow earnings with no or very
limited upfront investment.
While our main focus remains on furthering our
non-core divestment programme, we continue to identify and track
potential accretive bolt-on acquisition opportunities in
strategically attractive end markets and geographies for the
future, when our financial circumstances allow.
Innovation and sustainability
Innovation, particularly aligned to our
sustainability agenda, remains a priority for the Group. In July
our technical teams moved into our new China Innovation Centre
(CIC) in the Shanghai Chemical Industry Park. Construction of the
CIC was completed in six months, and later this year we expect to
commission a synthesis lab, further enhancing the CIC's value to
our businesses. The CIC will augment our local innovation
capabilities and strengthen our customer reach in the globally
significant Chinese market.
We continue to focus on the development of more
sustainable products both as a commercial proposition and as
integral to our purpose as an organisation. In the period we made
good progress towards launching several products with bio-based
feedstocks such as a new emulsion polymer platform for coatings in
CCS, and adhesives that support debonding for a more circular
economy in AS. These are supported by achieving ISCC PLUS
certification at seven of our key sites in the period, enabling us
to offer a mass balance approach for bio-based and circular raw
materials as part of our role at the centre of our value
chains.
Our industry-leading Product Sustainability
Scorecard continues to guide our innovation strategy - with 69% of
new products launched over the last twelve months having defined
sustainability benefits - and has received industry recognition,
most recently at the UK's Chemical Industry Awards. In April we
were named as one of Europe's Climate Leaders by the Financial
Times in partnership with data provider Statista. More recently we
retained our silver rating in EcoVadis' annual sustainability
assessment, which is only awarded to the top-performing 15% of all
companies assessed, and with an advanced rating for carbon
management.
Meanwhile we were very encouraged by an overall
nine-point improvement in our annual Net Promotor Score survey of
our customers completed in March 2024. Detailed survey data by
business line is being used by our teams to further improve our
product offering and enhance the experience of our customers
globally.
2024 outlook
Trading since the start of the year has been in
line with expectations, reflecting some volume recovery in a number
of businesses from historically low levels, but no sustained
broad-based end-market demand improvement as yet. Activity levels
and capacity utilisation across the Group remain significantly
below pre-pandemic levels. As previously indicated the Group
therefore continues to focus on delivering our speciality solutions
strategy, including portfolio management, alongside our activities
to maintain robust cash flow.
For the remainder of the year, we expect to make
continued progress with our previously announced actions to reduce
cost and complexity and to improve reliability. In the remainder of
the year we will also begin to benefit from the procurement and
production cost optimisation programmes that were initiated in the
first half, and which are expected to deliver £30-40m in annual
savings by the end of 2025. As previously indicated, our earnings
progress this year is being partially offset by some increases in
operating costs, mainly due to wage inflation and normalisation of
bonus accrual, compared with 2023. As a result, we continue to
expect to make some earnings progress (on a continuing Group basis
adjusting for the divested Compounds business) and be at least
modestly Free Cash Flow positive in 2024, even absent a broad-based
macroeconomic demand improvement.
We remain confident in our ambition to more than
double Synthomer's recent earnings over the medium term, through a
combination of our near-term self-help actions, end-market volume
recovery and strategic delivery.
Michael
Willome
Chief Executive Officer
13 August 2024
DIVISIONAL REVIEW - CONTINUING OPERATIONS
Coatings & Construction Solutions
(CCS)
Our most speciality-weighted division, CCS
continues to demonstrate the resilience and growth potential that
reflects its focus on delivering customer solutions that are
supported by the sustained alignment of people, capital and
strategy.
Six months ended 30
June
|
H1 2024
|
H1 2023
|
Change
|
Constant
currency1
|
|
£m
|
£m
|
%
|
%
|
Revenue
|
430.4
|
452.0
|
(4.8)%
|
(2.1)%
|
Volumes
(ktes)
|
271.8
|
270.0
|
+0.7%
|
|
EBITDA
|
53.0
|
54.9
|
(3.5)%
|
(0.9)%
|
EBITDA %
of revenue
|
12.3%
|
12.1%
|
|
|
Operating
profit - underlying
|
40.6
|
41.7
|
(2.6)%
|
-
|
Operating
profit - statutory
|
31.0
|
27.6
|
+12.3%
|
|
1 Underlying constant currency revenue and
profit retranslate current year results using the prior year's
average exchange rates.
Performance
Divisional revenue decreased by 2.1% in constant
currency to £430.4m (H1 2023: £452.0m), with a 0.7% increase in
volume compared with H1 2023, offset by lower pricing. The volume
growth principally reflects modestly improved buying behaviour from
our customers, particularly in the first quarter, reflecting some
tactical restocking and market share gains in coatings as we focus
on organic growth geographically.
Activity levels in our coatings and consumer end
markets have been more robust while construction activity was
disappointing in the period, as expected. Our activities for energy
end markets continue to deliver strong levels of growth.
Geographically, market conditions were relatively undifferentiated
in the period.
While reduced raw material costs compared with
H1 2023 were reflected in pricing, the division was successful in
improving unit margins, reflecting our focus on the speciality
nature of our offering for customers. Improved mix and robust cost
control produced an encouraging level of operating leverage at the
gross profit level, although this was mitigated as expected at the
EBITDA level by other operating cost increases compared with the
prior period. CCS nevertheless generated £53.0m of EBITDA (H1 2023:
£54.9m) in the period, increasing EBITDA margin to 12.3% (H1 2023:
12.1%).
CCS is typically the most seasonally weighted of
our divisions, although in 2024 we expect this effect to be
partially mitigated by our continued focus on delivering cost
actions which are weighted to the second half in the
division.
Strategy
CCS continues to focus on enhancing its organic
growth capability, including by extending our leading market
positions in niche European markets to other markets globally. We
are doing this through a more end-market aligned approach, with key
account management and a growing focus on value selling, both to
our global customers as well as regional leaders in our target
markets, particularly in the USA and Middle East.
In the period we have undertaken an intensive
review of our approach to innovation, exploring in particular
opportunities to become more end-market focused and accelerate time
to market. We are also reweighting our efforts, with a particular
focus on sustainability, to enhance the differentiation and margin
opportunity of our predominantly speciality product
portfolio.
All our plans are supported by, and integrated
with, our asset optimisation projects and other cost control and
capacity management activities. For example, our plans to exit our
Fitchburg, Massachusetts site continue to progress at pace
with production ceasing in July, ahead of schedule. By reorganising
our production activities we aim to improve asset utilisation rates
while reducing complexity. As part of these activities we are also
making modest new investments to further our strategic focus on
organic growth, including by improving the manufacturing
flexibility of our key facilities. In the period, we successfully
commissioned a small investment which enhances our coatings
capacity to support growth in the Middle East. With the recent
commissioning of the Group's new innovation centre in Shanghai we
are also increasing our focus on growing our customer base in
China.
Adhesive Solutions (AS)
We are encouraged by the ongoing progress we are
making to improve our cost competitiveness and increase the
reliability performance of our business, allowing us to regain
market share and deliver improving profits and margins as activity
levels modestly recover from Q4 2023 lows.
Six months ended 30
June
|
H1 2024
|
H1 2023
|
Change
|
Constant
currency1
|
|
£m
|
£m
|
%
|
%
|
Revenue
|
308.7
|
310.0
|
(0.4)%
|
+2.2%
|
Volumes
(ktes)
|
140.3
|
125.6
|
+11.7%
|
|
EBITDA
|
21.9
|
15.6
|
+40.4%
|
+42.9%
|
EBITDA %
of revenue
|
7.1%
|
5.0%
|
|
|
Operating
profit - underlying
|
5.2
|
1.4
|
+271.4%
|
+271.4%
|
Operating
loss - statutory
|
(8.6)
|
(12.3)
|
(30.1)%
|
|
1 Underlying constant currency revenue and
profit retranslate current year results using the prior year's
average exchange rates.
Performance
Divisional revenue was £308.7m (H1 2023:
£310.0m), an increase of 2.2% in constant currency. Volumes
significantly improved, with certain base products regaining market
share having been under significant pressure from global
competitors during the second half of 2023, and encouraging margin
improvement in a number of speciality areas. Volume growth was also
supported by some short-term customer restocking at the start of
the year. The more muted revenue growth in constant currency
reflected the pass-through of lower raw material costs compared
with H1 2023.
Within the division, speciality products (such
as rosins, amorphous polyolefins (APOs) and polybutadiene polymers)
performed well, particularly in unit margin terms, reflecting their
greater differentiation for customers, while in our more base
chemical products (particularly hydrocarbon resins for the tapes,
labels, packaging and plastics markets) we achieved improved gross
profit contribution from higher volumes as noted, benefitting from
greater reliability and our improved cost position.
Divisional EBITDA was substantially higher than
the prior year at £21.9m (H1 2023: £15.6m) with EBITDA margin of
7.1% (H1 2023: 5.0%) for the period. This was largely due to the
return to volume growth and the performance improvement programme
that was put in place in July 2023 by the new divisional management
team, which delivered £8m in benefits in H1 2024, although these
were partially offset by other operating cost increases as
previously disclosed.
Strategy
The immediate focus of the AS division remains
on the delivery of the performance improvement programme to
increase operational reliability and cost efficiency of the
acquired adhesive resins operations. Good progress has been made in
operations, with monitoring systems in place to identify yield and
other production efficiency opportunities, and taskforces on-site
at our main facilities in the US and the Netherlands to unlock
them. More recently we have focused on end-to-end supply
optimisation including planning, procurement and logistical
enhancements. We continue to target total run rate savings in
excess of £25m in 2025 from the programme. The division has also
successfully reduced inventory by c.£4m in the period.
In addition to the performance improvement
programme, we are increasingly focused on the longer-term
development of the AS division, building on our leading positions
in a range of speciality adhesive applications and our long-term
embedded relationships with many high-quality customers in
attractive end markets. Our differentiated strategy also recognises
that around 40% of revenues are generated from more volatile and
competitive base products. The majority of our investment for
future growth is intended to build on the strengths of our
speciality portfolio, with for example investments in the period to
increase our APO capacity at our Texas facility. We also continue
to strengthen customer relationship management and build our
portfolio of innovation projects, many of which will benefit from
sustainability considerations. Our customers showed increasing
interest in collaborating with us in this area during the period
and, having now put in place ISCC PLUS certification of our major
manufacturing sites, we are well-placed to partner with them to
create more sustainable value chains.
Meanwhile in the base product areas, we continue
to enhance cost competitiveness and reliability, with good progress
for example in our project to strengthen our supply chain for
hydrocarbon resin production in Europe during the
period.
Health & Protection and Performance Materials
(HPPM)
Heath & Protection volumes continue to
recover from historically low levels, with signs of improved unit
margins towards the end of the second quarter. Compounds was
successfully divested in April and our plans for our other
Performance Materials businesses are progressing.
Six months ended 30 June
(continuing)1
|
H1 2024
|
H1 2023
|
Change
|
Constant
currency2
|
|
£m
|
£m
|
%
|
%
|
Revenue
|
312.0
|
285.2
|
+9.4%
|
+13.8%
|
Volumes
(ktes)
|
302.5
|
249.7
|
+21.1%
|
|
EBITDA
|
14.8
|
12.3
|
+20.3%
|
+24.4%
|
EBITDA %
of revenue
|
4.7%
|
4.3%
|
|
|
Operating
profit/(loss) - underlying
|
1.2
|
(4.3)
|
n/m
|
n/m
|
Operating
loss - statutory
|
(4.3)
|
(5.4)
|
(20.4)%
|
|
1 North America Paper and Carpet and the
Compounds business have been reclassified as discontinued
operations.
2
Underlying constant currency revenue and profit
retranslate current year results using the prior year's average
exchange rates.
Continuing divisional performance
Divisional revenue was £312.0m (H1 2023:
£285.2m), driven by a 21.1% increase in volume, partially offset by
lower prices compared with H1 2023 reflecting lower raw materials
costs.
Volumes for NBR in Heath & Protection
improved by 36.5% compared to H1 2023 as the post-pandemic
imbalance between supply and demand reduced, driven mainly by
continued underlying hygiene demand growth megatrend. However, for
context, volumes have only now recovered to 2017 levels. Unit
margins and pricing remain low by historical standards but began to
improve slightly in the second quarter.
In our Performance Materials portfolio volumes
increased by 11.6%, with some businesses benefitting from the
disruption to supply chains into Europe from Asian markets in the
early part of the year.
As predominantly base chemicals businesses, the
division remains highly operationally leveraged to volumes and
capacity utilisation, and in aggregate has experienced a
significant improvement in profitability at the gross profit level
over the period. Performance also benefitted from our self-help
cost activities (including the mothballing of our facility in
Kluang, Malaysia which completed in the period as planned),
partially offset by the other operating cost increases described
elsewhere. Divisional EBITDA nonetheless increased to £14.8m (H1
2023: £12.3m), an EBITDA margin of 4.7% (H1 2023: 4.3%).
Strategy
Recognising much of the division has base
chemicals characteristics, our differentiated steering approach to
our core Health & Protection business is to focus on improving
cost efficiency across our value chain while enhancing our overall
value proposition to our customers through selective investment in
process and product innovation and sustainability. We have also
invested in enhancing our understanding of our end-markets and
customers, and recently redesignated our Speciality vinyl polymers
business as core following a review of its market
opportunities.
Given Health & Protection's strengths as a
global market leader in NBR manufacturing with significant
technology and manufacturing expertise, we are actively exploring a
number of potential partnership opportunities to capture growth and
value from this business with little or no capital investment. The
division's growth potential is also expected to benefit from
Synthomer's new China Innovation Centre in Shanghai, which was
formally opened as planned in July.
At the end of April 2024 we completed the
divestment of our latex compounding operations to Matco Latex
Services BV, reducing our manufacturing site footprint by 3 sites
(two in the Netherlands and one in Egypt), as described
elsewhere.
Our other non-core portfolio rationalisation
activities continued to progress during the period, including the
process to divest the SBR business for European paper and carpet
markets.
Safety
We continue to be proud of our safety
performance while recognising that there is always more to do, in
particular to complete the process of bringing more recently
acquired sites up to the standards of safety achieved elsewhere in
the portfolio.
The Recordable Case Rate (RCR) for the Group as
a whole remains top quartile for our industry, with two divisions
achieving no recordable injuries to employees and contractors
during the period. This reflects the hard work being undertaken
throughout the Group to continuously embed and strengthen the
safety systems and tools we have in place.
Meanwhile, our Process Safety Event Rate (PSER)
was slightly higher than the very strong 2023 performance and more
in line with 2022 levels. The primary causes of our process safety
events are asset integrity issues and human error which together
account for 75% of the events. The former are being addressed
through our ongoing capital expenditure programmes, while we have a
human factor analysis programme in place to address the
latter.
We continue to monitor and evolve our approach
to drive safety performance improvements, focusing on reducing both
our headline 'lagging' indicators RCR and PSER but also
increasingly on a number of 'leading' indicators. In the period we
have introduced two new leading indicators around major accident
hazard barrier effectiveness checks and on internal and external
incident learning.
Longer-term trends continue to clearly
demonstrate that the longer sites are part of Synthomer and our SHE
(safety, health and environment) management system, the better
their performance.
Six months ended 30 June
(continuing)
|
H1 2024
|
H1 2023
|
Change
|
RCR
per 100,000
hours for employees and contractors
|
|
|
Absolute
|
CCS
|
0.29
|
0.20
|
+0.09
|
AS
|
-
|
0.30
|
(0.30)
|
HPPM
|
-
|
-
|
-
|
Continuing
Group
|
0.13
|
0.13
|
-
|
PSER per 100,000 hours for
employees and contractors
|
|
|
Absolute
|
CCS
|
0.19
|
0.10
|
+0.09
|
AS
|
0.69
|
0.14
|
+0.55
|
HPPM
|
0.12
|
0.06
|
+0.06
|
Continuing
Group
|
0.24
|
0.09
|
+0.15
|
FINANCIAL REVIEW
Group revenue, EBITDA and operating profit - continuing
operations
Revenue for the continuing Group of £1,051.1m
(H1 2023: £1,047.2m) increased by 3.5% in constant currency. This
principally reflects an 10.7% increase in volume driven by a
recovery of some of the substantial volume declines experienced in
2023, offset by pass-through of lower raw material input prices
relative to the prior year period.
EBITDA for the continuing Group was £76.0m (H1
2023: £72.8m), benefitting from our self-help cost actions and
operating leverage, partially offset by increases in operating
costs as expected, mainly due to wage inflation and normalisation
of bonus accrual. Corporate costs increased to £13.7m in the period
(H1 2022: £10.0m), mainly due to wage inflation, bonus accrual,
timing of operating expenditures and higher expenditure in relation
to implementing our sustainability objectives. Depreciation and
amortisation was £47.0m (H1 2023: £47.7m), resulting in underlying
operating profit for the continuing Group of £29.0m (H1 2023:
£25.1m).
On a statutory basis, including the Special
Items excluded from underlying measures (see below), this resulted
in an operating loss for the continuing Group of £(2.2)m (H1 2023:
£(7.1)m).
Six months ended 30 June
2024, £m
|
CCS
|
AS
|
HPPM
|
Corp.
|
Continuing
operations
|
Dis-continued
|
Total
Group
|
Revenue
|
430.4
|
308.7
|
312.0
|
-
|
1,051.1
|
9.7
|
1,060.8
|
EBITDA
|
53.0
|
21.9
|
14.8
|
(13.7)
|
76.0
|
2.6
|
78.6
|
EBITDA % of
revenue
|
12.3%
|
7.1%
|
4.7%
|
|
7.2%
|
|
7.4%
|
Operating profit/(loss) -
underlying
|
40.6
|
5.2
|
1.2
|
(18.0)
|
29.0
|
2.4
|
31.4
|
Operating profit/(loss) -
statutory
|
31.0
|
(8.6)
|
(4.3)
|
(20.3)
|
(2.2)
|
(0.8)
|
(3.0)
|
Six
months ended 30 June 2023, £m
|
CCS
|
AS
|
HPPM
|
Corp.
|
Continuing
operations
|
Dis-continued
|
Total
Group
|
Revenue
|
452.0
|
310.0
|
285.2
|
-
|
1,047.2
|
56.1
|
1,103.3
|
EBITDA
|
54.9
|
15.6
|
12.3
|
(10.0)
|
72.8
|
1.7
|
74.5
|
EBITDA %
of revenue
|
12.1%
|
5.0%
|
4.3%
|
|
7.0%
|
|
6.8%
|
Operating
profit - underlying
|
41.7
|
1.4
|
(4.3)
|
(13.7)
|
25.1
|
0.8
|
25.9
|
Operating
profit - statutory
|
27.6
|
(12.3)
|
(5.4)
|
(17.0)
|
(7.1)
|
62.8
|
55.7
|
Full year
ended 31 December 2023, £m
|
CCS
|
AS
|
HPPM
|
Corp.
|
Continuing
operations
|
Dis-continued
|
Total
Group
|
Revenue
|
820.2
|
581.7
|
538.7
|
-
|
1,940.6
|
80.6
|
2,021.2
|
EBITDA
|
100.1
|
31.2
|
26.3
|
(20.2)
|
137.4
|
1.7
|
139.1
|
EBITDA %
of revenue
|
12.2%
|
5.4%
|
4.9%
|
|
7.1%
|
|
6.9%
|
Operating
profit - underlying
|
74.3
|
(7.5)
|
(6.0)
|
(27.4)
|
33.4
|
0.4
|
33.8
|
Operating
profit - statutory
|
42.1
|
(32.7)
|
(15.3)
|
(33.6)
|
(39.5)
|
57.2
|
17.7
|
Special Items - continuing operations
The following items of income and expense have
been reported as Special Items - continuing operations and have
been excluded from EBITDA and other underlying metrics:
Six months ended 30 June
|
H1 2024
|
H1 2023
|
FY 2023
|
|
£m
|
£m
|
£m
|
Amortisation of acquired intangibles
|
(22.8)
|
(24.3)
|
(49.3)
|
Restructuring and site closure costs
|
(6.7)
|
(6.6)
|
(14.7)
|
Acquisition costs and related gains
|
(1.2)
|
(1.3)
|
(2.0)
|
Sale of
businesses
|
(0.5)
|
-
|
(0.1)
|
Impairment charge
|
-
|
-
|
(5.6)
|
Regulatory fine
|
-
|
-
|
(0.7)
|
Abortive
bond costs
|
-
|
-
|
(0.5)
|
Total impact on operating
profit - continuing operations
|
(31.2)
|
(32.2)
|
(72.9)
|
Fair
value movement on unhedged interest rate derivatives
|
-
|
(1.8)
|
(1.8)
|
Loss on
extinguishment of financing facilities
|
(1.3)
|
(4.6)
|
(4.7)
|
Total impact on loss/profit
before taxation - continuing operations
|
(32.5)
|
(38.6)
|
(79.4)
|
Taxation
Special Items
|
-
|
-
|
(1.7)
|
Taxation
on Special Items
|
3.0
|
(4.9)
|
4.5
|
Total impact on loss/profit
for the period - continuing operations
|
(29.5)
|
(43.5)
|
(76.6)
|
Amortisation of acquired intangibles reflects
the amortisation on the customer lists, patents, trademarks and
trade secrets that arose on historic acquisitions, including the
2022 acquisition of the adhesive resins business. The intangible
assets arising on the acquisition are amortised over a period of
8-20 years.
Restructuring and site closure costs in H1 2024
mainly comprised a £1.6m charge in relation to site rationalisation
activity in Malaysia, £1.2m costs in relation to the ongoing
integration of the acquired adhesive resins business, £1.2m in
relation to the onerous contract arising from the earlier
divestment of the European tyre cord business, and £2.8m in
relation to enacting the new strategy and the alignment of the
business into its new divisions.
Acquisition costs of £1.2m relate to the
acquisition of the adhesive resins business.
Sale of businesses costs of £0.5m
comprise costs incurred associated with potential future
divestments.
The Taxation on Special Items for continuing
operations in H1 2024 was a tax credit of £3.0m mainly relating to
deferred tax arising on the amortisation of acquired tax
intangibles.
Discontinued operations
On 30 April 2024, the Group completed the
divestment of its latex compounding operations ('the Compounds
business') to Matco Latex Services BV, resulting in a net cash
inflow of £20.6m. The profit on disposal before the recycling of
translation reserves was £1.4m. The Compounds business is reported
as a discontinued operation in these results. In accordance with
IFRS 5, discontinued revenues have been reduced by £5.7m,
representing the revenue earned to the date of sale by the
continuing operations from inter-company sales to the Compounds
business. Continuing revenues have been increased by the same
amount.
In the period, £2.8m of net losses were
recognised in relation to Special Items - discontinued operations
(H1 2023: £36.4m gain), comprising the profit on disposal of £1.4m
noted above and £(4.4)m of translation losses recycled from
reserves on the disposal, as well as £0.2m of gains related to
other previous disposals offset by £(0.4)m of costs in relation to
the closure of the North America Paper & Carpet
business.
Finance costs
Six months ended 30 June
|
H1 2024
|
H1 2023
|
FY 2023
|
|
£m
|
£m
|
£m
|
Interest
payable
|
(33.8)
|
(35.8)
|
(70.6)
|
Interest
receivable
|
6.8
|
5.0
|
10.2
|
Net
interest expense on defined benefit obligation
|
(0.9)
|
(1.1)
|
(2.7)
|
Interest
element of lease payments
|
(1.0)
|
(0.7)
|
(1.8)
|
Finance costs -
underlying
|
(28.9)
|
(32.6)
|
(64.9)
|
Fair
value movement on unhedged interest rate derivatives
|
-
|
(1.8)
|
(1.8)
|
Loss on
extinguishment of financing facilities
|
(1.3)
|
(4.6)
|
(4.7)
|
Finance costs -
statutory
|
(30.2)
|
(39.0)
|
(71.4)
|
Underlying finance costs decreased to £28.9m (H1
2023: £32.6m) and comprise interest on the Group's financing
facilities, interest rate swaps, amortisation of associated debt
costs and IAS 19 pension interest costs in respect of our defined
benefit pension schemes. The reduction in net interest payable
mainly reflects increased interest receivable following receipt of
the proceeds of the rights issue and lower gross debt, offset by
increased bond interest as a result of the bond refinancing (see
below).
The Group recognised as Special Items a total of
£1.3m in finance costs relating to the write-off of previous issue
costs on extinguishment of financing facilities, as a result of the
bond refinancing.
Taxation
The Group has calculated its best estimate of
the annual effective corporate income tax rate we expect for the
full year, resulting in an underlying tax charge of £0.2m for
continuing operations for H1 2024. As in the prior year the
estimated tax rate is very dependent on the level of underlying
profit or loss and the geographical mix of that profit or loss.
Therefore, there is some fluctuation in the effective tax rate
applied when comparing the relative periods (H1 2024: 200.0%, H1
2023: 22.0%).
Non-controlling interest
The Group continues to hold 70% of Revertex
(Malaysia) Sdn Bhd and its subsidiaries. These entities form a
relatively minor part of the Group, so the impact on underlying
performance from non-controlling interests is not
significant.
Earnings per share
Earnings per share is calculated based on the
weighted average number of shares in issue during the year. The
weighted average number of shares for H1 2024 was 163.5m (H1 2023:
63.4m on a comparable basis), reflecting the 20 to 1 share
consolidation and the issuance of new shares at a discount under
the rights issue in October 2023. As at 13 August 2024, the Company
had 163.6m shares in issue.
Underlying earnings per share is 1.3 pence for
the year, up from (8.0) pence in H1 2023 on a comparable basis,
reflecting the improved earnings. The statutory earnings per share
is (18.8) pence (H1 2023: (19.0) pence on a comparable
basis).
Currency
The Group presents its consolidated financial
statements in sterling and conducts business in many currencies. As
a result, it is subject to foreign currency risk due to exchange
rate movements, which affect the Group's translation of the results
and underlying net assets of its operations. To manage this risk,
the Group uses foreign currency borrowings, forward contracts and
currency swaps to hedge non-sterling net assets, which are
predominantly denominated in euros, US dollars and Malaysian
ringgits.
In H1 2024 the Group experienced a translation
headwind of £2.3m on EBITDA, with average FX rates against our
three principal currencies of €1.17, $1.28 and MYR 5.99 to the
pound.
Given the global nature of our customer and
supplier base, the impact of transactional foreign exchange can be
very different from translational foreign exchange. We are able to
partially mitigate the transaction impact by matching supply and
administrative cost currencies with sales currencies. To reduce
volatility which might affect the Group's cash or income statement,
the Group hedges net currency transaction exposures at the point of
confirmed order, using forward foreign exchange contracts. The
Group's policy is, where practicable, to hedge all exposures on
monetary assets and liabilities.
Cash performance
The following table summarises the movement in
net debt and is in the format used by management:
Six months ended 30
June
|
H1 2024
|
H1 2023
|
FY 2023
|
|
£m
|
£m
|
£m
|
Opening net
debt
|
(499.7)
|
(1,024.9)
|
(1,024.9)
|
Underlying operating profit (excluding joint
ventures)
|
30.5
|
25.2
|
32.4
|
Movement
in working capital
|
(28.9)
|
11.9
|
80.6
|
Depreciation of property, plant and equipment
|
41.9
|
44.8
|
96.5
|
Amortisation of other intangible assets
|
5.3
|
3.8
|
8.8
|
Capital
expenditure
|
(38.2)
|
(33.9)
|
(84.0)
|
Operating Cash
Flow1
|
10.6
|
51.8
|
134.3
|
Net
interest paid
|
(26.1)
|
(24.7)
|
(54.3)
|
Tax
received/(paid)
|
(6.9)
|
(4.5)
|
9.3
|
Pension
funding
|
(9.8)
|
(5.7)
|
(7.3)
|
Adjustment for share-based payments charge
|
0.8
|
1.1
|
1.8
|
Dividends
received from joint ventures
|
0.2
|
0.8
|
1.9
|
Free Cash
Flow
|
(31.2)
|
18.8
|
85.7
|
Cash
impact of settlement of interest rate derivative
contracts
|
-
|
12.1
|
12.1
|
Cash
impact of restructuring and site closure costs
|
(10.4)
|
(10.8)
|
(28.0)
|
Cash
impact of acquisition costs
|
(0.9)
|
(4.4)
|
(1.9)
|
Payment
of EC fine settlement amount
|
(39.1)
|
-
|
-
|
Proceeds
on sale of business
|
24.3
|
206.1
|
208.2
|
Purchase
of adhesive resins business
|
-
|
(8.3)
|
(18.4)
|
Rights
issue (costs)/proceeds
|
(4.7)
|
-
|
265.5
|
Repayment
of principal portion of lease liabilities
|
(6.7)
|
(5.8)
|
(12.4)
|
Dividends
paid
|
-
|
-
|
-
|
Foreign
exchange and other movements
|
7.8
|
21.4
|
14.4
|
Movement in net
debt
|
(60.9)
|
229.1
|
525.2
|
Closing net
debt
|
(560.6)
|
(795.8)
|
(499.7)
|
1
Operating Cash Flow is defined as Total Group
EBITDA plus/minus net working capital movement less capital
expenditure.
Underlying operating profit increased to £30.5m
reflecting the trading performance described above. The net working
capital outflow of £28.9m was a result of increasing activity
levels (in part due to seasonal variations between December and
June) and higher raw materials prices since the previous year end,
offset by inflows from the receivables financing facilities and
active inventory management.
In December 2022, the Group put in place
two-year, non-recourse receivables financing facilities for a
maximum committed amount of €200m. Factored receivables assigned
under the facilities amounted to £128.0m net at 30 June 2024 (30
June 2023: £ 139.2m net, 31 December 2023: £110.6m net). Under the
facilities, the risks and rewards of ownership are transferred to
the assignees. The duration of the committed facilities has been
extended to 31 January 2027.
Depreciation reduced reflecting the capital
expenditure profile, whilst amortisation of other intangibles
increased due to the Pathway business transformation programme.
Capital expenditure was £38.2m (H1 2023: £33.9m), principally for
Pathway and recurring SHE and sustenance expenditure. The Group
continues to anticipate broadly similar levels of capital
expenditure to FY 2023 in FY 2024.
Net interest paid increased to £26.1m (H1 2023:
£24.7m) reflecting increased and rephased bond interest costs,
offset by increased interest receipts from cash raised in the
October 2023 rights issue.
Net tax paid was £6.9m (H1 2023: £4.5m)
reflecting tax payments on account made in the year.
The cash impact of Special Items including
restructuring and site closure costs and acquisition costs was an
outflow of £11.3m.
Group debt is denominated in euros and dollars.
Both the euro and the dollar weakened relative to sterling during
H1 2024, leading to a foreign exchange gain in net debt.
Financing and liquidity
At 30 June 2024, net debt was £560.6m (30 June
2023: £795.8m, 31 December 2023: £499.7m). The increase since the
year end principally reflects settlement of the EC fine in January,
the divestment proceeds of the Compounds business and the Free Cash
Flow movements noted above.
In April, we successfully tendered for €370m of
our bonds due 2025 reducing gross debt and extending maturities by
issuing €350m of bonds due 2029.
As at 30 June 2024, committed borrowing
facilities principally comprised: a €300m RCF maturing in July
2027, €350m of five-year 7.375% senior unsecured loan notes
maturing May 2029, the remaining €150m outstanding of five-year
3.875% senior unsecured loan notes maturing July 2025 and the UK
Export Finance (UKEF) facilities of €288m and $230m both maturing
October 2027. At 30 June 2024, the RCF was undrawn and the UKEF
facilities were fully drawn. The Group's net debt: EBITDA for the
purposes of the leverage ratio covenant increased from 4.2x at 31
December 2023 to 4.7x at 30 June 2024, principally due to the
higher net debt at the period end, as described
elsewhere.
The RCF and the UKEF facilities are subject to
one leverage ratio covenant. For prudence, the Group agreed in
March 2024 to extend the period of temporary covenant relaxation to
ensure that appropriate headroom was maintained. Accordingly, the
net debt: EBITDA ratios required under the covenant have been set
at not more than 6.0x in June 2024, 5.75x in December 2024, 5.0x in
June 2025 and 4.75x in December 2025. Reducing leverage further
towards our 1-2x medium-term target range remains a key priority
for the Group.
The Group expects net financing costs of
c.£60-65m in 2024 and c.£65-70m in 2025 as a result of higher
interest rates, the recent bond refinancing and other changes to
the Group's financing arrangements. The Group's committed liquidity
at 30 June 2024 was in excess of £500m.
Balance sheet
Net assets of the Group decreased by 1.9% to
£1,140.2m at 30 June 2024, mainly reflecting the loss in the
period.
Provisions
The Group provisions balance decreased to £37.6m
compared with a balance of £41.5m as at 31 December 2023, mainly
reflecting cash utilisation of £4.8m in the period, most notably in
relation to onerous contracts and restructuring and site
rationalisation activities.
Retirement benefit plans
The Group's principal funded defined benefit
pension schemes are in the UK and the USA and are both closed to
new entrants and future accrual. The Group also operates an
unfunded defined benefit scheme in Germany and various other
defined contribution overseas retirement benefit
arrangements.
The Group's net retirement obligation decreased
by £14.0m to £50.7m at 30 June 2024 (30 June 2023: £62.6m, 31
December 2023: £64.7m), and reflects the market value of assets and
the valuation of liabilities in accordance with IAS 19, including
an asset of £22.2m for the UK scheme. This reduction largely
comprised £9.8m of cash contributions and actuarial gains of £3.7m.
During 2024 the Group is committed to making c.£19m in
contributions to the UK scheme, a portion of which was deferred
from 2023 as agreed with the pension trustees.
Consolidated income statement
for the six months ended 30 June
2024
|
30 June 2024
(unaudited)
|
30 June
2023 (unaudited)
|
|
Underlying performance
£m
|
Special
Items
£m
|
IFRS
£m
|
Underlying performance
£m
|
Special
Items
£m
|
IFRS
£m
|
Continuing
operations
Revenue
|
1,051.1
|
-
|
1,051.1
|
1,047.2
|
-
|
1,047.2
|
Company and subsidiaries operating
profit before
Special Items
|
28.1
|
-
|
28.1
|
24.3
|
-
|
24.3
|
Amortisation of acquired intangibles
|
-
|
(22.8)
|
(22.8)
|
-
|
(24.3)
|
(24.3)
|
Restructuring and site closure costs
|
-
|
(6.7)
|
(6.7)
|
-
|
(6.6)
|
(6.6)
|
Acquisition costs and related gains
|
-
|
(1.2)
|
(1.2)
|
-
|
(1.3)
|
(1.3)
|
Sale of
businesses
|
-
|
(0.5)
|
(0.5)
|
-
|
-
|
-
|
Regulatory Fine
|
-
|
-
|
-
|
-
|
-
|
-
|
Abortive
bond costs
|
-
|
-
|
-
|
-
|
-
|
-
|
Impairment
charge
|
-
|
-
|
-
|
-
|
-
|
-
|
Company
and subsidiaries operating profit
|
28.1
|
(31.2)
|
(3.1)
|
24.4
|
(32.2)
|
(7.8)
|
Share of
joint ventures
|
0.9
|
-
|
0.9
|
0.7
|
-
|
0.7
|
Operating
profit /
(loss)
|
29.0
|
(31.2)
|
(2.2)
|
25.1
|
(32.2)
|
(7.1)
|
Interest payable
|
(33.8)
|
-
|
(33.8)
|
(35.8)
|
-
|
(35.8)
|
Interest receivable
|
6.8
|
-
|
6.8
|
5.0
|
-
|
5.0
|
Fair value
(loss) / gain on unhedged interest rate derivatives
|
-
|
-
|
-
|
-
|
(1.8)
|
(1.8)
|
Loss on
extinguishment of financing facilities
|
-
|
(1.3)
|
(1.3)
|
-
|
(4.6)
|
(4.6)
|
Net
interest expense on defined benefit obligations
|
(0.9)
|
-
|
(0.9)
|
(1.1)
|
-
|
(1.1)
|
Interest
element of lease payments
|
(1.0)
|
-
|
(1.0)
|
(0.7)
|
-
|
(0.7)
|
Finance costs
|
(28.9)
|
(1.3)
|
(30.2)
|
(32.6)
|
(6.4)
|
(39.0)
|
Profit / (Loss) before
taxation
|
0.1
|
(32.5)
|
(32.4)
|
(7.5)
|
(38.6)
|
(46.1)
|
Taxation
|
(0.2)
|
3.0
|
2.8
|
2.2
|
(4.9)
|
(2.7)
|
(Loss) / profit
for
the
period from
continuing operations
|
(0.1)
|
(29.5)
|
(29.6)
|
(5.3)
|
(43.5)
|
(48.8)
|
Profit /
(loss) for the period from discontinued operations attributable to
the equity holders of the parent
|
1.8
|
(3.2)
|
(1.4)
|
0.1
|
36.3
|
36.4
|
(Loss) / profit
for the
period
|
1.7
|
(32.7)
|
(31.0)
|
(5.2)
|
(7.2)
|
(12.4)
|
(Loss) /
profit attributable to non-controlling interests
|
(0.4)
|
0.1
|
(0.3)
|
(0.1)
|
(0.2)
|
(0.3)
|
(Loss) /
profit attributable to equity holders of the parent
|
2.1
|
(32.8)
|
(30.7)
|
(5.1)
|
(7.0)
|
(12.1)
|
|
1.7
|
(32.7)
|
(31.0)
|
(5.2)
|
(7.2)
|
(12.4)
|
Earnings per
share
|
|
|
|
|
|
|
-
Basic from continuing operations
|
(0.1)p
|
(18.0)p
|
(18.1)p
|
(8.4)p
|
(68.5)p
|
(76.9)p
|
-
Diluted from continuing operations
|
(0.1)p
|
(18.0)p
|
(18.1)p
|
(8.4)p
|
(68.5)p
|
(76.9)p
|
|
|
|
|
|
|
|
-
Basic
|
1.3p
|
(20.1)p
|
(18.8)p
|
(8.0)p
|
(11.0)p
|
(19.0)p
|
-
Diluted
|
1.3p
|
(20.1)p
|
(18.8)p
|
(8.0)p
|
(11.0)p
|
(19.0)p
|
Consolidated income statement
for the six months ended 30 June
2024 (continued)
|
|
Year
ended 31 December 2023 (audited)
|
|
|
Underlying performance
£m
|
Special
Items
£m
|
IFRS
£m
|
Continuing
operations
Revenue
|
|
1,940.6
|
-
|
1,940.6
|
Company and subsidiaries operating
profit before
Special Items
|
|
32.0
|
-
|
32.0
|
Amortisation of acquired intangibles
|
|
-
|
(49.3)
|
(49.3)
|
Restructuring and site closure costs
|
|
-
|
(14.7)
|
(14.7)
|
Acquisition costs and related gains
|
|
-
|
(2.0)
|
(2.0)
|
Sale of
businesses
|
|
-
|
(0.1)
|
(0.1)
|
Regulatory Fine
|
|
-
|
(0.7)
|
(0.7)
|
Abortive
bond costs
|
|
-
|
(0.5)
|
(0.5)
|
Impairment charge
|
|
-
|
(5.6)
|
(5.6)
|
Company
and subsidiaries operating profit
|
|
32.0
|
(72.9)
|
(40.9)
|
Share of
joint ventures
|
|
1.4
|
-
|
1.4
|
Operating
profit /
(loss)
|
|
33.4
|
(72.9)
|
(39.5)
|
Interest payable
|
|
(70.6)
|
-
|
(70.6)
|
Interest receivable
|
|
10.2
|
-
|
10.2
|
Fair value
gain on unhedged interest rate derivatives
|
|
-
|
(1.8)
|
(1.8)
|
Loss on
extinguishment of financing facilities
|
|
|
(4.7)
|
(4.7)
|
Net
interest expense on defined benefit obligations
|
|
(2.7)
|
-
|
(2.7)
|
Interest
element of lease payments
|
|
(1.8)
|
-
|
(1.8)
|
Finance costs
|
|
(64.9)
|
(6.5)
|
(71.4)
|
Profit / (loss) before
taxation
|
|
(31.5)
|
(79.4)
|
(110.9)
|
Taxation
|
|
3.5
|
2.8
|
6.3
|
Profit / (loss)
for
the
year from
continuing operations
|
|
(28.0)
|
(76.6)
|
(104.6)
|
Profit /
(loss) for the year from discontinued operations attributable to
the equity holders of the parent
|
|
(1.6)
|
39.4
|
37.8
|
(Loss)
for the
year
|
|
(29.6)
|
(37.2)
|
(66.8)
|
Profit /
(loss) attributable to non-controlling interests
|
|
0.4
|
(0.2)
|
0.2
|
Profit /
(loss) attributable to equity holders of the parent
|
|
(30.0)
|
(37.0)
|
(67.0)
|
|
|
(29.6)
|
(37.2)
|
(66.8)
|
Earnings per
share
|
|
|
|
|
-
Basic from continuing operations
|
|
(33.4)p
|
(89.4)p
|
(122.8)p
|
-
Diluted from continuing operations
|
|
(33.4)p
|
(89.4)p
|
(122.8)p
|
|
|
|
|
|
-
Basic
|
|
(35.3)p
|
(43.2)p
|
(78.5)p
|
-
Diluted
|
|
(35.3)p
|
(43.2)p
|
(78.5)p
|
Consolidated statement of comprehensive
income
for the six months ended 30 June
2024
|
30 June 2024
(unaudited)
|
30 June
2023 (unaudited)
|
|
Equity holders of the
parent
£m
|
Non-controlling
interests
£m
|
Total
£m
|
Equity
holders of the parent
£m
|
Non-controlling interests
£m
|
Total
£m
|
(Loss) /
profit for the period
|
(30.7)
|
(0.3)
|
(31.0)
|
(12.1)
|
(0.3)
|
(12.4)
|
Actuarial gains
|
3.5
|
-
|
3.5
|
3.3
|
-
|
3.3
|
Tax
relating to components of other
comprehensive income
|
1.9
|
-
|
1.9
|
(0.7)
|
-
|
(0.7)
|
Total
items that
will not
be
reclassified to profit
or
loss
|
5.4
|
-
|
5.4
|
2.6
|
-
|
2.6
|
Exchange differences
on translation
of foreign
operations
|
(8.1)
|
(0.7)
|
(8.8)
|
(53.5)
|
(0.8)
|
(54.3)
|
Exchange differences
recycled on
sale of
business
|
4.4
|
-
|
4.4
|
(0.5)
|
-
|
(0.5)
|
Fair
value gain / (loss) on hedged interest
derivatives
|
1.2
|
-
|
1.2
|
(0.1)
|
-
|
(0.1)
|
Gain /
(loss) on net investment hedges taken to equity
|
5.7
|
-
|
5.7
|
(2.2)
|
-
|
(2.2)
|
Total items that may be
reclassified subsequently to profit or loss
|
3.2
|
(0.7)
|
2.5
|
(56.3)
|
(0.8)
|
(57.1)
|
Other
comprehensive (expense)
/
income for the
period
|
8.6
|
(0.7)
|
7.9
|
(53.7)
|
(0.8)
|
(54.5)
|
Total
comprehensive (expense) /
income for
the
period
|
(22.1)
|
(1.0)
|
(23.1)
|
(65.8)
|
(1.1)
|
(66.9)
|
|
|
|
|
|
|
| |
|
|
Year
ended 31 December 2023 (audited)
|
|
|
|
|
Equity
holders of the parent
£m
|
Non-controlling interests
£m
|
Total
£m
|
(Loss) /
gain for the year
|
|
|
|
(67.0)
|
0.2
|
(66.8)
|
Actuarial gains
|
|
|
|
2.9
|
-
|
2.9
|
Tax
relating to components of other
comprehensive income
|
|
|
|
(1.0)
|
-
|
(1.0)
|
Total items that will not be reclassified to profit or loss
|
|
|
|
1.9
|
-
|
1.9
|
Exchange differences
on translation
of foreign
operations
|
|
|
|
(58.3)
|
(0.8)
|
(59.1)
|
Exchange
differences recycled on sale of business
|
|
|
|
(0.5)
|
-
|
(0.5)
|
Fair
value gain on hedged interest derivatives
|
|
|
|
(7.7)
|
-
|
(7.7)
|
Gains on
net investment hedges taken to equity
|
|
|
|
1.0
|
-
|
1.0
|
Total
items that may be reclassified subsequently to profit or
loss
|
|
|
|
(65.5)
|
(0.8)
|
(66.3)
|
Other comprehensive
expense for
the year
|
|
|
|
(63.6)
|
(0.8)
|
(64.4)
|
Total comprehensive
expense for
the year
|
|
|
|
(130.6)
|
(0.6)
|
(131.2)
|
Consolidated statement of changes in equity
for the six months ended 30 June
2024
|
|
Share
capital
£m
|
Share
premium
£m
|
Capital redemption
reserve
£m
|
Hedging & translation
reserve
£m
|
Retained
earnings
£m
|
Total equity holdings
of
the
parent
£m
|
Non-controlling
interests
£m
|
Total
Equity
£m
|
At 1 January 2024
|
|
1.6
|
925.9
|
0.9
|
10.4
|
209.8
|
1,148.6
|
13.4
|
1,162.0
|
Loss for
the period
|
|
-
|
-
|
-
|
-
|
(30.7)
|
(30.7)
|
(0.3)
|
(31.0)
|
Other
comprehensive (expense) / income for the period
|
|
-
|
-
|
-
|
3.2
|
5.4
|
8.6
|
(0.7)
|
7.9
|
Total comprehensive
expense for the
period
|
|
-
|
-
|
-
|
3.2
|
(25.3)
|
(22.1)
|
(1.0)
|
(23.1)
|
Share-based payments
|
|
-
|
-
|
-
|
-
|
1.3
|
1.3
|
-
|
1.3
|
At 30 June 2024
(unaudited)
|
|
1.6
|
925.9
|
0.9
|
13.6
|
185.8
|
1,127.8
|
12.4
|
1,140.2
|
|
|
Share
capital
£m
|
Share
premium
£m
|
Capital
redemption
reserve
£m
|
Hedging
& translation reserve
£m
|
Retained
earnings
£m
|
Total
equity holdings of
the
parent
£m
|
Non-controlling
interests
£m
|
Total
Equity
£m
|
At 1
January 2023
|
|
46.7
|
620.0
|
0.9
|
75.9
|
273.5
|
1,017.0
|
14.0
|
1,031.0
|
Loss for the period
|
|
-
|
-
|
-
|
-
|
(12.1)
|
(12.1)
|
(0.3)
|
(12.4)
|
Other
comprehensive (expense) / income for the
period
|
|
-
|
-
|
-
|
(56.3)
|
2.6
|
(53.7)
|
(0.8)
|
(54.5)
|
Total
comprehensive income for the period
|
|
-
|
-
|
-
|
(56.3)
|
(9.5)
|
(65.8)
|
(1.1)
|
(66.9)
|
Share-based payments
|
|
-
|
-
|
-
|
-
|
(0.8)
|
(0.8)
|
-
|
(0.8)
|
At 30
June 2023 (unaudited)
|
|
46.7
|
620.0
|
0.9
|
19.6
|
263.2
|
950.4
|
12.9
|
963.3
|
|
Share
capital
£m
|
Share
premium
£m
|
Capital
redemption
reserve
£m
|
Hedging
& translation reserve
£m
|
Retained
earnings
£m
|
Total
equity holdings of
the
parent
£m
|
Non-controlling
interests
£m
|
Total
Equity
£m
|
At 1
January 2023
|
46.7
|
620.0
|
0.9
|
75.9
|
273.5
|
1,017.0
|
14.0
|
1,031.0
|
Loss for the year
|
-
|
-
|
-
|
-
|
(67.0)
|
(67.0)
|
0.2
|
(66.8)
|
Other
comprehensive income for the
year
|
-
|
-
|
-
|
(65.5)
|
1.9
|
(63.6)
|
(0.8)
|
(64.4)
|
Total
comprehensive income / (expense) for the year
|
-
|
-
|
-
|
(65.5)
|
(65.1)
|
(130.6)
|
(0.6)
|
(131.2)
|
Share
consolidation
|
(46.5)
|
46.5
|
-
|
-
|
-
|
-
|
-
|
-
|
Issue of
shares
|
1.4
|
259.4
|
-
|
-
|
-
|
260.8
|
-
|
260.8
|
Share-based payments
|
-
|
-
|
-
|
-
|
1.4
|
1.4
|
-
|
1.4
|
At 31
December 2023 (audited)
|
1.6
|
925.9
|
0.9
|
10.4
|
209.8
|
1,148.6
|
13.4
|
1,162.0
|
Consolidated balance sheet
as at 30 June 2024
|
30 June
2024
(unaudited)
£m
|
30 June
2023
(unaudited)
£m
|
31
December 2023
(audited)
£m
|
Non-current
assets
|
|
|
|
Goodwill
|
454.9
|
464.5
|
465.7
|
Acquired
intangible assets
|
429.1
|
476.6
|
452.5
|
Other
intangible assets
|
70.4
|
66.7
|
71.1
|
Property, plant and equipment
|
680.5
|
722.0
|
705.7
|
Deferred tax assets
|
46.7
|
25.0
|
36.8
|
Defined benefit asset
|
22.2
|
11.5
|
16.5
|
Investment in joint ventures
|
7.7
|
7.6
|
7.5
|
Total
non-current assets
|
1,711.5
|
1,773.9
|
1,755.8
|
Current
assets
|
|
|
|
Inventories
|
342.7
|
374.5
|
344.1
|
Trade and
other receivables
|
271.7
|
262.7
|
213.0
|
Current tax assets
|
5.2
|
26.4
|
8.8
|
Cash and
cash equivalents
|
273.3
|
232.9
|
371.3
|
Derivative financial
instruments
|
6.1
|
11.4
|
12.2
|
Assets
classified as held for sale
|
5.5
|
-
|
1.5
|
Total
current assets
|
904.5
|
907.9
|
950.9
|
Total
assets
|
2,616.0
|
2,681.8
|
2,706.7
|
Current
liabilities
|
|
|
|
Borrowings
|
(0.4)
|
(33.9)
|
(0.7)
|
Trade and other payables
|
(424.1)
|
(442.9)
|
(431.3)
|
Lease
liabilities
|
(12.5)
|
(11.1)
|
(13.8)
|
Current
tax liabilities
|
(25.9)
|
(24.7)
|
(28.0)
|
Provisions for other liabilities and charges
|
(11.2)
|
(15.2)
|
(11.9)
|
Derivative financial instruments
|
(2.0)
|
-
|
(2.4)
|
Total
current liabilities
|
(476.1)
|
(527.8)
|
(488.1)
|
Non-current liabilities
|
|
|
|
Borrowings
|
(833.5)
|
(994.8)
|
(870.3)
|
Trade and other payables
|
(0.2)
|
(0.4)
|
(0.2)
|
Lease
liabilities
|
(36.3)
|
(47.0)
|
(41.5)
|
Deferred tax liabilities
|
(30.4)
|
(42.7)
|
(33.8)
|
Retirement benefit obligations
|
(72.9)
|
(74.1)
|
(81.2)
|
Provisions for other liabilities and charges
|
(26.4)
|
(31.7)
|
(29.6)
|
Total
non-current liabilities
|
(999.7)
|
(1,190.7)
|
(1,056.6)
|
Total
liabilities
|
(1,475.8)
|
(1,718.5)
|
(1,544.7)
|
Net
assets
|
1,140.2
|
963.3
|
1,162.0
|
Equity
|
|
|
|
Share
capital
|
1.6
|
46.7
|
1.6
|
Share
premium
|
925.9
|
620.0
|
925.9
|
Capital
redemption reserve
|
0.9
|
0.9
|
0.9
|
Hedging
and translation reserve
|
13.6
|
19.6
|
10.4
|
Retained
earnings
|
185.8
|
263.2
|
209.8
|
Equity
attributable to equity
holders of the
parent
|
1,127.8
|
950.4
|
1,148.6
|
Non-controlling
interests
|
12.4
|
12.9
|
13.4
|
Total
equity
|
1,140.2
|
963.3
|
1,162.0
|
Consolidated cash flow statement
for the six months ended 30 June
2024
|
Six months
ended
30 June
2024
(unaudited)
£m
|
Six
months ended
30
June 2023
(unaudited)
£m
|
Year
ended
31
December 2023
(audited)
£m
|
Operating
|
|
|
|
|
|
|
Cash
generated from operations (Note
5)
|
|
(10.6)
|
|
78.0
|
|
195.0
|
-
Interest received
|
6.8
|
|
5.0
|
|
10.2
|
|
-
Interest paid
|
(31.9)
|
|
(29.0)
|
|
(62.7)
|
|
-
Interest element of lease payments
|
(1.0)
|
|
(0.7)
|
|
(1.8)
|
|
Net
interest paid
|
|
(26.1)
|
|
(24.7)
|
|
(54.3)
|
- UK
corporation tax paid
|
-
|
|
(3.0)
|
|
(2.9)
|
|
- Overseas corporate tax
paid
|
(6.9)
|
|
(1.5)
|
|
12.2
|
|
Total tax
paid
|
|
(6.9)
|
|
(4.5)
|
|
9.3
|
Net
cash inflow /
(outflow) from
operating activities
|
|
(43.6)
|
|
48.8
|
|
150.0
|
Investing
|
|
|
|
|
|
|
Dividends
received from joint ventures
|
|
0.2
|
|
0.8
|
|
1.9
|
Purchase
of property, plant and equipment and other intangible assets
|
|
(38.2)
|
|
(33.9)
|
|
(84.0)
|
Purchase
of business
|
|
-
|
|
(8.3)
|
|
(18.4)
|
Proceeds
from sale of businesses
|
|
24.3
|
|
206.1
|
|
208.2
|
Net cash inflow / (outflow)
from investing activities
|
|
(13.7)
|
|
164.7
|
|
107.7
|
Financing
|
|
|
|
|
|
|
Dividends
paid to non-controlling interests
|
|
(0.2)
|
|
-
|
|
-
|
Proceeds
on issue of shares
|
|
(4.7)
|
|
-
|
|
265.5
|
Settlement of equity-settled share-based payments
|
|
(0.1)
|
|
(0.3)
|
|
(0.4)
|
Repayment
of principal portion of lease liabilities
|
|
(6.7)
|
|
(5.8)
|
|
(12.4)
|
Repayment
of borrowings
|
|
(315.9)
|
|
(556.3)
|
|
(892.0)
|
Proceeds
of borrowings
|
|
298.8
|
|
345.4
|
|
548.4
|
Net cash (outflow) from
financing activities
|
|
(28.8)
|
|
(217.0)
|
|
(90.9)
|
Increase/
(Decrease) in cash,
cash equivalents
and
bank overdrafts
during the
period
|
|
(86.1)
|
|
(3.5)
|
|
166.8
|
Cash and
cash equivalents and bank overdrafts at 1 January
|
|
370.6
|
|
209.2
|
|
209.2
|
Foreign
exchange
|
|
(11.6)
|
|
(6.7)
|
|
(5.4)
|
Cash and cash equivalents
and bank overdrafts at period end
|
|
272.9
|
|
199.0
|
|
370.6
|
See note 10 for further details of
cash flows from discontinued operations
Notes to the consolidated financial
statements
for the six months ended 30 June
2024
1
Basis of preparation
Synthomer plc is a public company
limited company incorporated in the United Kingdom and registered
in England under the Companies Act. The Company is listed on the
London Stock Exchange and the address of the registered office is
Temple Fields, Harlow, Essex CM20 2BH. These interim financial
statements for the six month period ended 30 June 2024 have been
prepared on the basis of the policies set out in the 2023 annual
financial statements and in accordance with UK adopted
International Accounting Standard 34 'Interim Financial Reporting'
and the Disclosure Guidance and Transparency Rules sourcebook of
the UK's Financial Conduct Authority. These interim financial
statements do not comprise statutory accounts within the meaning of
section 434 of the Companies Act 2006 and do not include all the
notes normally included in annual financial statements. Statutory
accounts for the year ended 31 December 2023 were approved by the
Board of Directors on 12 March 2024 and delivered to the Registrar
of Companies. The report of the auditors on those accounts was
unqualified, did not contain an emphasis of matter paragraph and
did not contain any statement under section 498 of the Companies
Act 2006.
These interim financial statements
have been reviewed, not audited.
Going concern
The Group meets its day-to-day
working capital requirements through its bank facilities. The
current economic conditions continue to create uncertainty,
particularly over the level of demand for the Group's products. The
Group's forecasts and projections take account of reasonably
possible changes in trading performance and a severe but plausible
downside scenario has been prepared, linked to our principal risks.
Various mitigating actions have been identified so that, should
such a scenario crystallise, the Group could take action quickly to
significantly reduce costs and cash outflows as demonstrated during
the course of the COVID-19 pandemic in 2020.
As at 30 June 2024, the consolidated
balance sheet reflects a net asset position of £1,140m and the
liquidity of the Group had headroom of more than £500m of cash and
undrawn committed facilities. The earliest maturity date of our
facilities is July 2025. Debt leverage covenant limits for the term
loans and revolving credit facility are set at a ratio of 6.0x at
30 June 2024, reducing to 5.75x at 31 December 2024, 5.00x at June
2025, 4.75x at 31 December 2025, 3.50x at June 2026 and 3.25x
thereafter. At the half year, the net debt position was £560.6m and
our covenant ratio was 4.7x. The Group continues to deliver on
reducing net debt and strengthening the balance sheet. Our severe
but plausible downside scenario, offset by mitigation actions as
required, does not indicate a debt leverage covenant break on any
of the dates through to September 2025. Having considered the
outcome of these assessments, the Directors have, at the time of
approving the interim report and financial statements, a reasonable
expectation that the Company and the Group will have adequate
resources to continue in operational existence for the foreseeable
future. Thus, they continue to adopt the going concern basis of
accounting in preparing the financial statements.
Goodwill and acquired
intangible assets
The Group
tests goodwill annually for impairment, or more frequently if there
are indications that goodwill might be impaired. In the six months
to 30 June 2024 no such indications were identified.
Key
sources of estimation uncertainty
The key assumptions concerning the
future, and other key sources of estimation uncertainty at the
reporting date that may have a significant risk of causing a
material adjustment to the carrying amounts of assets and
liabilities within the next financial year are set out in the 2023
Annual Report. Estimates and underlying assumptions are reviewed on
an ongoing basis and at 30 June 2024 there were no changes to
existing estimates and assumptions and no new sources of estimation
uncertainty were identified.
2.
Accounting policies
The annual financial statements of
Synthomer plc are prepared in accordance with UK-adopted
International Accounting Standards and the requirements of the
Companies Act 2006. The same accounting policies and methods of
computations are followed in these financial statements as in the
most recent audited annual financial statements. Effective from 1
January 2024, no updates to IFRSs have been made that would affect
the Group.
3
Special Items
IFRS and Underlying performance
The IFRS profit measures show the
performance of the Group as a whole and as such include all sources
of income and expense, including both one-off items and those that
do not relate to the Group's ongoing businesses. To provide
additional clarity on the ongoing trading performance of the
Group's businesses, management uses 'Underlying' performance as an
Alternative Performance Measure to plan for, control and assess the
performance of the segments. Underlying performance differs from
the IFRS measures as it excludes Special Items.
Special Items
Special Items are disclosed
separately in order to provide a clearer indication of the Group's
Underlying performance.
Special Items are either irregular,
and therefore including them in the assessment of a segment's
performance would lead to a distortion of trends, or are technical
adjustments which ensure the Group's financial statements are in
compliance with IFRS but do not reflect the operating performance
of a segment in the year, or both. An example of the latter is the
amortisation of acquired intangibles, which principally relates to
acquired customer relationships. The Group incurs costs, which are
recognised as an expense in the income statement, in maintaining
these customer relationships. The Group considers that the
exclusion of the amortisation charge on acquired intangibles from
Underlying performance avoids the potential double counting of such
costs and therefore excludes it as a Special Item from Underlying
performance.
The following are consistently
disclosed separately as Special Items in order to provide a clearer
indication of the Group's Underlying performance:
• Restructuring and
site closure costs;
• Sale of business
or significant asset;
• Acquisition costs
and related gains;
• Amortisation of
acquired intangible assets;
• Impairment of
non-current assets;
• Fair value
adjustments in respect of derivative financial instruments where
hedge accounting is not applied;
• Items of income
and expense that are considered material, either by their size and
/ or nature;
• Tax impact of
above items; and
• Settlement of
prior period tax issues.
Special Items comprise:
|
Six months ended June
2024 (unaudited)
£m
|
Six
months ended June 2023 (unaudited)
£m
|
Year
ended 31 December 2023 (audited)
£m
|
Amortisation of acquired intangibles
|
(22.8)
|
(24.3)
|
(49.3)
|
Restructuring and site closure costs
|
(6.7)
|
(6.6)
|
(14.7)
|
Acquisition costs and related gains
|
(1.2)
|
(1.3)
|
(2.0)
|
Sale of
businesses
|
(0.5)
|
-
|
(0.1)
|
Regulatory Fine
|
-
|
-
|
(0.7)
|
Abortive
bond costs
|
-
|
-
|
(0.5)
|
Impairment charge
|
-
|
-
|
(5.6)
|
Total
impact on operating
loss
|
(31.2)
|
(32.2)
|
(72.9)
|
Finance costs
|
|
|
|
Fair
value gain on unhedged interest derivatives
|
-
|
(1.8)
|
(1.8)
|
Loss on
extinguishment of financing facilities
|
(1.3)
|
(4.6)
|
(4.7)
|
Total
impact on profit
before taxation
|
(32.5)
|
(38.6)
|
(79.4)
|
Taxation
Special Items
|
-
|
-
|
(1.7)
|
Taxation
on Special Items
|
3.0
|
(4.9)
|
4.5
|
Total
impact on profit
for
the
period- continuing
operations
|
(29.5)
|
(43.5)
|
(76.6)
|
Discontinued
Operations
|
|
|
|
Restructuring and site closure costs
|
(0.4)
|
-
|
(3.7)
|
Sale of
businesses
|
(2.8)
|
62.0
|
61.3
|
Impairment charge
|
-
|
-
|
(0.8)
|
Taxation
on Special Items
|
-
|
(25.7)
|
(17.4)
|
Total impact on profit for
the period- discontinued operations
|
(3.2)
|
36.3
|
39.4
|
Total
impact on profit
for the period
|
(32.7)
|
(7.2)
|
(37.2)
|
3
Special Items (continued)
Amortisation of acquired intangibles
reflects the amortisation on the customer lists, patents,
trademarks and trade secrets that arose on historic acquisitions,
including the 2022 acquisition of the adhesive resins business. The
intangible assets arising on the acquisition are amortised over a
period of 8-20 years.
Restructuring and site closure costs
in 2024 comprise:
• A £1.6m charge in
relation to site closure costs associated with mothballing our NBR
plant in Kluang, Malaysia;
• A £1.2m charge in
relation to the ongoing integration of the adhesive resins business
acquired in 2022;
• A £1.2m charge in
relation to the onerous contract arising from the earlier
divestment of the European tyre cord business
• A further £2.8m,
in relation to enacting the new the strategy and the alignment of
the business into its new divisions.
Restructuring and site closure costs
in 2023 comprised £2.4m integration costs for the adhesive resins
business and £4.2m in relation to enacting the new the strategy and
the alignment of the business into its new divisions which became
effective in 2023.
Acquisition costs and related gains
of £1.2m are for the acquisition of the adhesive resins business.
Acquisition costs in 2023 also related to the adhesive resins
acquisition.
Sale of businesses (continuing
operations) costs of £0.5m comprise costs incurred associated with
potential future divestments.
Sale of businesses (discontinued
operations) represents the loss recognised on the sale of the latex
compounding ("Compounds") operations after recycling of FX
reserves, which completed on 30 April 2024. Refer to note 11 for
further details. In the prior year sale of businesses principally
comprised of the gain on sale of the Laminates, Films and Coated
Fabrics business.
The tax on Special Items for
continuing operations was £3.0m (H1 2023: £4.9m tax credit; FY
2023: £4.6m tax credit). This mainly relates to deferred tax
arising on the amortisation of acquired tax
intangibles.
4
Segmental analysis
The Group's Executive Committee,
chaired by the Chief Executive Officer, examines the Group's
performance.
The Group's reportable segments are
as follows:
Coatings & Construction Solutions (CCS)
Our specialist polymers enhance the
sustainable performance of a wide range of coatings and
construction products. We work across architectural and masonry
coatings, mortar modification, waterproofing and flooring, fibre
bonding, and energy solutions.
Adhesive Solutions (AS)
Our adhesive solutions bond, modify
and compatibilise surfaces and components for products including
tapes and labels, packaging, hygiene, tyres and plastic
modification, helping improve permeability, strength, elasticity,
damping, dispersion and grip.
Health & Protection and Performance Materials
(HPPM)
We help enhance protection and
performance in a wide range of industries including medical glove
manufacture, speciality paper, food packaging, carpet and
artificial turf, gel foam elastomers, and vinyl-coated seating
fabrics.
The Group's Executive Committee is
the chief operating decision maker and primarily uses a measure of
earnings before interest, tax, depreciation and amortisation
(EBITDA) to assess the performance of the operating segments. No
information is provided to the Group's Executive Committee at the
segment level concerning interest income, interest expense, income
tax or other material non-cash items.
No single customer accounts for more
than 10% of the Group's revenue.
A segmental analysis of Underlying
performance and Special Items is shown below.
|
Six months ended 30 June 2024
(unaudited)
|
|
Continuing
Operations
|
Discontinued
Operations
|
Total
|
2024
|
Coatings & Construction
Solutions
£m
|
Adhesive
Solutions
£m
|
Health & Protection and
Performance Materials
£m
|
Corporate
£m
|
Total
£m
|
£m
|
Total
£m
|
Revenue
|
|
|
|
|
|
|
|
Total revenue
|
430.4
|
308.7
|
313.7
|
-
|
1,052.8
|
9.7
|
1,062.5
|
Inter-segmental revenue
|
-
|
-
|
(1.7)
|
-
|
(1.7)
|
-
|
(1.7)
|
|
430.4
|
308.7
|
312.0
|
-
|
1,051.1
|
9.7
|
1,060.8
|
EBITDA
|
53.0
|
21.9
|
14.8
|
(13.7)
|
76.0
|
2.6
|
78.6
|
Depreciation and amortisation
|
(12.4)
|
(16.7)
|
(13.6)
|
(4.3)
|
(47.0)
|
(0.2)
|
(47.2)
|
Operating
profit /
(loss) before Special Items
|
40.6
|
5.2
|
1.2
|
(18.0)
|
29.0
|
2.4
|
31.4
|
Special
Items
|
(9.6)
|
(13.8)
|
(5.5)
|
(2.3)
|
(31.2)
|
(3.2)
|
(34.4)
|
Operating
profit /
(loss)
|
31.0
|
(8.6)
|
(4.3)
|
(20.3)
|
(2.2)
|
(0.8)
|
(3.0)
|
Finance
costs
|
|
|
|
|
|
|
(30.2)
|
Profit/ (loss) before
taxation
|
|
|
|
|
|
|
(33.2)
|
4
Segmental analysis (continued)
|
|
|
|
Six
months ended 30 June 2023 (unaudited)
|
|
Continuing Operations
|
Discontinued Operations
|
Total
|
2023
|
Coatings
& Construction Solutions
£m
|
Adhesive
Solutions
£m
|
Health
& Protection and Performance Materials
£m
|
Corporate
£m
|
Total
£m
|
£m
|
Total
£m
|
Revenue
|
|
|
|
|
|
|
|
Total revenue
|
452.0
|
310.0
|
291.4
|
-
|
1,053.4
|
56.1
|
1,109.5
|
Inter-segmental revenue
|
-
|
-
|
(6.2)
|
-
|
(6.2)
|
-
|
(6.2)
|
|
452.0
|
310.0
|
285.2
|
-
|
1,047.2
|
56.1
|
1,103.3
|
EBITDA
|
54.9
|
15.6
|
12.3
|
(10.0)
|
72.8
|
1.7
|
74.5
|
Depreciation and amortisation
|
(13.2)
|
(14.2)
|
(16.6)
|
(3.7)
|
(47.7)
|
(0.9)
|
(48.6)
|
Operating profit / (loss)
before Special Items
|
41.7
|
1.4
|
(4.3)
|
(13.7)
|
25.1
|
0.8
|
25.9
|
Special
Items
|
(14.1)
|
(13.7)
|
(1.1)
|
(3.3)
|
(32.2)
|
62.0
|
29.8
|
Operating profit
|
27.6
|
(12.3)
|
(5.4)
|
(17.0)
|
(7.1)
|
62.8
|
55.7
|
Finance
costs
|
|
|
|
|
|
|
(39.0)
|
Profit/
(loss) before taxation
|
|
|
|
|
|
|
16.7
|
|
|
|
|
Year
ended 31 December 2023 (audited)
|
|
Continuing Operations
|
Discontinued Operations
|
Total
|
2023
|
Coatings
& Construction Solutions
£m
|
Adhesive
Solutions
£m
|
Health
& Protection and Performance Materials
£m
|
Corporate
£m
|
Total
£m
|
£m
|
Total
£m
|
Revenue
|
|
|
|
|
|
|
|
Total revenue
|
820.2
|
581.7
|
549.3
|
-
|
1,951.2
|
80.6
|
2,031.8
|
Inter-segmental revenue
|
-
|
-
|
(10.6)
|
-
|
(10.6)
|
-
|
(10.6)
|
|
820.2
|
581.7
|
538.7
|
-
|
1,940.6
|
80.6
|
2,021.2
|
EBITDA
|
100.1
|
31.2
|
26.3
|
(20.2)
|
137.4
|
1.7
|
139.1
|
Depreciation and amortisation
|
(25.8)
|
(38.7)
|
(32.3)
|
(7.2)
|
(104.0)
|
(1.3)
|
(105.3)
|
Operating profit / (loss)
before Special Items
|
74.3
|
(7.5)
|
(6.0)
|
(27.4)
|
33.4
|
0.4
|
33.8
|
Special
Items
|
(32.2)
|
(25.2)
|
(9.3)
|
(6.2)
|
(72.9)
|
56.8
|
(16.1)
|
Operating profit / (loss)
|
42.1
|
(32.7)
|
(15.3)
|
(33.6)
|
(39.5)
|
57.2
|
17.7
|
Finance
costs
|
|
|
|
|
|
|
(71.4)
|
Profit/
(loss) before taxation
|
|
|
|
|
|
|
(53.7)
|
|
|
|
|
|
|
|
| |
5
Reconciliation of operating profit / (loss) to cash generated from
operations
Continuing and discontinued operations:
|
Six
months
ended 30
June
2024
(unaudited)
£m
|
Six
months
ended 30
June
2023
(unaudited)
£m
|
Year
ended 31
December 2023
(audited)
£m
|
Operating (loss)
/ profit
|
(3.0)
|
55.7
|
17.7
|
Less:
share of profits of joint ventures
|
(0.9)
|
(0.7)
|
(1.4)
|
|
(3.9)
|
55.0
|
16.3
|
Adjustments for:
|
|
|
|
-
Depreciation of property, plant and equipment
|
35.8
|
39.2
|
85.0
|
-
Depreciation of right of use assets
|
6.1
|
5.6
|
11.5
|
-
Amortisation of other intangibles
|
5.3
|
3.8
|
8.8
|
-
Share-based payments
|
0.8
|
1.1
|
1.8
|
-
Special Items
|
34.4
|
(29.8)
|
16.1
|
Cash
impact of restructuring and site closure costs
|
(10.4)
|
(10.8)
|
(28.0)
|
Cash
impact of acquisition costs and related gains
|
(0.9)
|
(4.4)
|
(1.9)
|
Cash
impact of settlement of interest rate derivative
contracts
|
-
|
12.1
|
12.1
|
Pension
funding in excess of service cost
|
(9.8)
|
(5.7)
|
(7.3)
|
(Increase) / decrease in inventories
|
(8.1)
|
13.7
|
45.7
|
Decrease
/ (increase) in trade and other receivables
|
(69.7)
|
1.6
|
52.7
|
(Decrease) / increase in trade and other payables
|
48.9
|
(3.4)
|
(17.8)
|
Payment
of EC fine settlement amount
|
(39.1)
|
-
|
-
|
Cash
generated from operations
|
(10.6)
|
78.0
|
195.0
|
6
Taxation
The group has calculated its best
estimate of the annual effective corporate income tax rate we
expect for the full year, resulting in a half year underlying tax
charge of £0.2m for continuing operations. We estimate the rate by
applying the expected corporate income tax rates for each tax
jurisdiction in which we operate. As in the prior year the
estimated tax rate is very dependent on the level of underlying
profit or loss and the geographical mix of that profit or loss.
Therefore, there is some fluctuation in the effective tax rate
applied when comparing the relative periods: H1 2024 200.0%,
H1 2023: 22.0%; FY 2023: 5.9%.
The tax on Special Items for
continuing operations was £3.0m (H1 2023: £4.9m tax credit; FY
2023: £4.6m tax credit). This mainly relates to deferred tax
arising on the amortisation of acquired tax
intangibles.
The group is within the scope of the
OECD Pillar Two model rules. Pillar Two legislation was enacted in
the United Kingdom, the jurisdiction in which the parent company is
incorporated, and is effective from 1 January 2024. The group
applies the IAS 12 exception to recognising and disclosing
information about deferred tax assets and liabilities related to
Pillar Two income taxes.
Under the legislation, the group is
liable to pay a top-up tax for the difference between its GloBE
effective tax rate per jurisdiction and the 15% minimum rate. The
group has estimated weighted average effective tax rates that
exceed 15% in all jurisdictions in which it operates and therefore
does not expect to be subject to the global minimum top-up tax in
the year ending 31 December 2024.
7
Earnings per share
|
|
Six months ended 30 June
2024
(unaudited)
|
Six
months ended 30 June 2023
(unaudited)
|
|
|
Underlying
performance
|
Special
Items
|
IFRS
|
Underlying
performance
|
Special
Items
|
IFRS
|
Profit /
(loss) attributable to equity holders of the parent
|
|
|
|
|
|
|
|
- continuing
|
£m
|
(0.1)
|
(29.5)
|
(29.6)
|
(5.3)
|
(43.5)
|
(48.8)
|
- total
|
£m
|
2.7
|
(32.8)
|
(30.7)
|
(5.1)
|
(7.0)
|
(12.1)
|
Number
of
shares
|
|
|
|
|
|
|
|
Weighted
average number of ordinary shares -
basic
|
'000
|
|
|
163,474
|
|
|
63,433
|
Effect of dilutive potential ordinary shares
|
'000
|
|
|
852
|
|
|
202
|
Weighted average number of ordinary shares - diluted
|
'000
|
|
|
164,326
|
|
|
63,635
|
Earnings
per share for
profit from continuing operations
|
|
|
|
|
|
|
|
Basic
earnings per share
|
pence
|
(0.1)
|
(18.0)
|
(18.1)
|
(8.4)
|
(68.5)
|
(76.9)
|
Diluted
earnings per share
|
pence
|
(0.1)
|
(18.0)
|
(18.1)
|
(8.4)
|
(68.5)
|
(76.9)
|
Earnings
per share for
profit from discontinued operations
|
|
|
|
|
|
|
|
Basic
earnings per share
|
pence
|
1.3
|
(2.0)
|
(0.7)
|
0.4
|
57.5
|
57.9
|
Diluted
earnings per share
|
pence
|
1.3
|
(2.0)
|
(0.7)
|
0.4
|
57.5
|
57.9
|
Earnings
per share for
profit attributable to equity holders of the
parent
|
|
|
|
|
|
|
|
Basic
earnings per share
|
pence
|
1.3
|
(20.1)
|
(18.8)
|
(8.0)
|
(11.0)
|
(19.0)
|
Diluted
earnings per share
|
pence
|
1.3
|
(20.1)
|
(18.8)
|
(8.0)
|
(11.0)
|
(19.0)
|
|
|
|
|
|
|
|
| |
|
|
Year
ended 31 December 2023
(audited)
|
|
|
|
|
Underlying
performance
|
Special
Items
|
IFRS
|
|
|
|
Profit /
(loss) attributable to equity holders of the parent
|
|
|
|
|
|
|
|
- continuing
|
£m
|
(28.4)
|
(76.4)
|
(104.8)
|
|
|
|
- total
|
£m
|
(30.0)
|
(37.0)
|
(67.0)
|
|
|
|
Number of shares
|
|
|
|
|
|
|
|
Weighted
average number of ordinary shares -
basic
|
'000
|
|
|
85,382
|
|
|
|
Effect of dilutive potential ordinary shares
|
'000
|
|
|
251
|
|
|
|
Weighted average number of ordinary shares - diluted
|
'000
|
|
|
85,633
|
|
|
|
Earnings per share for profit from
continuing operations
|
|
|
|
|
|
|
|
Basic
earnings per share
|
pence
|
(33.4)
|
(89.4)
|
(122.8)
|
|
|
|
Diluted
earnings per share
|
pence
|
(33.4)
|
(89.4)
|
(122.8)
|
|
|
|
Earnings per share for profit from
discontinued operations
|
|
|
|
|
|
|
|
Basic
earnings per share
|
pence
|
(1.9)
|
46.2
|
44.3
|
|
|
|
Diluted
earnings per share
|
pence
|
(1.9)
|
46.2
|
44.3
|
|
|
|
Earnings per share for profit
attributable to equity holders of the parent
|
|
|
|
|
|
|
|
Basic
earnings per share
|
pence
|
(35.3)
|
(43.2)
|
(78.5)
|
|
|
|
Diluted
earnings per share
|
pence
|
(35.3)
|
(43.2)
|
(78.5)
|
|
|
|
|
|
|
|
|
|
|
| |
8
Analysis of net debt
|
30 June
2024
(unaudited)
£m
|
30 June
2023
(unaudited)
£m
|
31
December 2023
(audited)
£m
|
Bank
overdrafts
|
(0.4)
|
(33.9)
|
(0.7)
|
Current
liabilities
|
(0.4)
|
(33.9)
|
(0.7)
|
Bank
loans
|
(416.0)
|
(551.1)
|
(421.9)
|
€520m
3.875% senior unsecured loan notes due 2025
|
(126.7)
|
(443.7)
|
(448.4)
|
€350m
7.375% senior unsecured loan notes due 2029
|
(290.8)
|
-
|
-
|
Non-current
liabilities
|
(833.5)
|
(994.8)
|
(870.3)
|
Total
borrowings
|
(833.9)
|
(1,028.7)
|
(871.0)
|
Cash and
cash equivalents
|
273.3
|
232.9
|
371.3
|
Net Debt
|
(560.6)
|
(795.8)
|
(499.7)
|
Net debt is defined in the glossary
of terms. Capitalised debt costs which have been recognised as a
reduction in borrowings in the financial statements, amounted to
£15.7m at 30 June 2024 (30 June 2023: £10.2m, 31 December 2023:
£10.5m).
9
Defined benefit schemes
We have updated the value of the
defined benefit plan assets to reflect their market value as at 30
June 2024. Actuarial gains or losses are recognised in the
Consolidated Statement of Comprehensive Income in accordance with
the Group's accounting policy. We have updated the liabilities to
reflect the change in the discount rate and other assumptions. The
Group's net pension liability decreased by £14.0m to £50.7m, which
includes an asset of £22.2m for the UK scheme. This £14.0m
reduction largely comprised £9.8m of cash contributions and
actuarial gains of £3.7m.
10
Discontinued operations
On 30 April 2024, the Group sold its
Compounds business to Matco Latex Services BV.
A summary of the proceeds and
disposed assets is set out below:
|
Total
|
|
£m
|
Consideration
|
|
Cash Consideration
|
24.5
|
Total
|
24.5
|
|
|
Net
assets sold:
|
|
Goodwill
|
7.5
|
Property Plant and
equipment
|
5.4
|
Inventory
|
5.5
|
Cash and cash equivalents
|
3.4
|
Trade and other
receivables
|
7.3
|
Trade and other payables
|
(7.4)
|
Total
|
21.7
|
|
|
Transaction costs in the
period
|
(1.4)
|
Gain
on sale before recycling of translation reserve and
tax
|
1.4
|
Reclassification of foreign currency
translation reserve
|
(4.4)
|
Tax expense on sale
|
-
|
Gain
on sale after recycling of translation reserve and
tax
|
(3.0)
|
|
|
|
Total
|
|
£m
|
Cash
Inflow of sale of business
|
|
Cash Consideration
|
24.5
|
Transaction costs paid in the
period
|
(0.5)
|
Cash consideration after transaction
costs
|
24.0
|
Cash outflow with business
|
(3.4)
|
Total
|
20.6
|
Including prior period transaction
costs, the total proceeds were £24.5m (€28.6m) and the total
transaction costs were £1.5m (€1.8m), giving total proceeds after
transaction costs of £23.0m (€26.8m).
10
Discontinued operations (continued)
Financial performance and cash flow
information
Financial information in respect of
the discontinued operation during the period and the impact of the
transaction is set out below:
The Compounds businesses formed part
of the Health & Protection and Performance Materials
division.
|
Six months ended 30 June 2024
(unaudited)
|
Six
months ended 30 June 2023 (unaudited)
|
|
Compounds
£m
|
Laminates, Films and Coated
Fabrics
£m
|
NA Paper and
Carpet
£m
|
Total
£m
|
Compounds
£m
|
Laminates, Films and Coated Fabrics
£m
|
NA Paper
and Carpet
£m
|
Total
£m
|
Revenue
|
9.8
|
-
|
-
|
9.8
|
15.5
|
28.0
|
12.7
|
56.2
|
EBITDA
|
2.6
|
-
|
-
|
2.6
|
2.9
|
2.5
|
(3.7)
|
1.7
|
Depreciation and amortisation - Underlying
performance
|
(0.2)
|
-
|
-
|
(0.2)
|
(0.2)
|
-
|
(0.7)
|
(0.9)
|
Operating Profit / (loss) -
Underlying performance
|
2.4
|
-
|
-
|
2.4
|
2.7
|
2.5
|
(4.4)
|
0.8
|
Special
Items
|
(3.0)
|
0.2
|
(0.4)
|
(3.2)
|
-
|
62.0
|
-
|
62.0
|
Operating Profit / (loss) -
IFRS
|
(0.6)
|
0.2
|
(0.4)
|
(0.8)
|
2.7
|
64.5
|
(4.4)
|
62.8
|
Financial
costs
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Profit / (loss) before
taxation
|
(0.6)
|
0.2
|
(0.4)
|
(0.8)
|
2.7
|
64.5
|
(4.4)
|
62.8
|
Taxation
|
(0.6)
|
-
|
-
|
(0.6)
|
(0.7)
|
(25.7)
|
-
|
(26.4)
|
Profit / (loss) for the
period
|
(1.2)
|
0.2
|
(0.4)
|
(1.4)
|
2.0
|
38.8
|
(4.4)
|
36.4
|
|
Year
ended 31 December 2023 (audited)
|
|
|
Compounds
£m
|
Laminates, Films and Coated Fabrics
£m
|
NA Paper
and Carpet
£m
|
Total
£m
|
|
|
|
|
Revenue
|
30.3
|
28.0
|
22.3
|
80.6
|
|
|
|
|
EBITDA
|
4.7
|
2.5
|
(5.5)
|
1.7
|
|
|
|
|
Depreciation and amortisation - Underlying
performance
|
(0.4)
|
-
|
(0.9)
|
(1.3)
|
|
|
|
|
Operating
Profit / (loss) - Underlying performance
|
4.3
|
2.5
|
(6.4)
|
0.4
|
|
|
|
|
Special
Items
|
(0.2)
|
61.5
|
(4.5)
|
56.8
|
|
|
|
|
Operating
Profit / (loss) - IFRS
|
4.1
|
64.0
|
(10.9)
|
57.2
|
|
|
|
|
Financial
costs
|
-
|
-
|
-
|
-
|
|
|
|
|
Profit /
(loss) before taxation
|
4.1
|
64.0
|
(10.9)
|
57.2
|
|
|
|
|
Taxation
|
(1.8)
|
(17.6)
|
-
|
(19.4)
|
|
|
|
|
Profit /
(loss) for the period
|
2.3
|
46.4
|
(10.9)
|
37.8
|
|
|
|
|
The prior-year comparatives of the
consolidated income statement and the consolidated statement of
cash flows have been adjusted in accordance with IFRS 5 to report
the discontinued operations separately from continuing
operations.
10
Discontinued operations (continued)
Cash flows from discontinued operations
|
Six months ended 30 June 2024
(unaudited)
|
Six
months ended 30 June 2023 (unaudited)
|
|
Compounds
£m
|
Laminates, Films and Coated
Fabrics
£m
|
NA Paper and
Carpet
£m
|
Total
£m
|
Compounds
£m
|
Laminates, Films and Coated Fabrics
£m
|
NA Paper
and Carpet
£m
|
Total
£m
|
Net cash (outflow) / inflow
from operating activities
|
(3.6)
|
-
|
(0.4)
|
(4.0)
|
3.1
|
(2.8)
|
(4.4)
|
(4.1)
|
Net cash (outflow) / inflow
from investing activities
|
18.5
|
(0.1)
|
-
|
18.4
|
(0.1)
|
206.1
|
-
|
206.0
|
|
|
Year
ended 30 December 2023 (audited)
|
|
|
Compounds
£m
|
Laminates, Films and Coated Fabrics
£m
|
NA Paper
and Carpet
£m
|
Total
£m
|
Net cash
(outflow) / inflow from operating activities
|
|
7.5
|
(0.1)
|
(7.8)
|
(0.4)
|
Net cash
(outflow) / inflow from investing activities
|
|
(0.6)
|
208.2
|
-
|
207.6
|
11
Capital commitments
The capital expenditure authorised
but not provided for in the interim financial statements as at 30
June 2024 was £15.7m (30 June 2023: £25.4m; 31 December 2023:
£8.8m).
12
Related party transactions
Transactions between the Company and
its subsidiaries, which are related parties, have been eliminated
on consolidation and are not included in this note. Other than the
relationships with defined benefit pension schemes as disclosed in
note 29 of the 2023 Annual Report, there were no other related
party transactions requiring disclosure.
Kuala Lumpur Kepong Berhad holds 27%
of the Company's shares and is considered to be a related
party.
13
Seasonality
Historically, there has been no
visible fixed pattern to seasonality in H1 compared to H2
performance in the Group, but the seasonality of the business is
more significantly impacted by macroeconomic conditions which
remain uncertain.
14
Risks and uncertainties
The Group faces a number of risks
which, if they arise, could affect our ability to achieve our
strategic objectives. As with any business, risk assessment and the
implementation of mitigating actions and controls are vital to
successfully achieving the strategy. The Directors are responsible
for determining the nature of these risks and ensuring appropriate
mitigating actions are in place to manage them.
These principal risks are
categorised into the following types:
• Strategic
• Operational
• Compliance
• Financial
These risks are detailed on pages 48
to 55 of the 2023 Annual Report which is available on our website
at www.synthomer.com/investor-relations.
The Directors continuously monitor
the Group's risk environment and have not identified any
significant new or emerging risks or uncertainties which would have
a material impact on the Group's performance in the remaining part
of the year.
We continue to mitigate these risks
by following, at a minimum, any government mandated health and
safety requirements at our sites, by ensuring that we have multiple
sources of raw materials, and by maintaining a diverse customer
base.
15
Glossary of terms
EBITDA
|
EBITDA is
calculated as operating profit from continuing operations before
depreciation, amortisation and Special Items.
|
Operating
profit
|
Operating
profit represents profit from continuing activities before finance
costs and taxation.
|
Special
Items
|
Special
Items are irregular items, whose inclusion could lead to a
distortion of trends, or technical adjustments which ensure the
Group's financial statements are in compliance with IFRS, but do
not reflect the operating performance of the segment in the year,
or both.
These
include the following, inter alia, which are disclosed separately
as Special Items in order to provide a clearer indication of the
Group's Underlying performance:
· Restructure and site closure costs;
· Sale of a business or significant asset;
· Acquisition costs and related gains;
· Amortisation of acquired intangible assets;
· Impairment of non-current assets;
· Fair value adjustments in respect of derivative financial
instruments where hedge accounting is not applied;
· Items of income and expense that are considered material,
either by their size and / or nature;
· Tax impact of above items; and
· Settlement of prior period tax
issues.
|
Underlying performance
|
This
represents the statutory performance of the Group under IFRS,
excluding Special Items.
|
Free Cash
Flow
|
The
movement in net debt before financing activities, foreign exchange
and the cash impact of Special Items, asset disposals and business
combinations.
|
Net
debt
|
Net debt
represents cash and cash equivalents less short- and long-term
borrowings.
|
Leverage
|
Net debt
divided by EBITDA.
The
Group's financial covenants are calculated using the accounting
standards adopted by the Group at 31 December 2018 and accordingly,
leverage excludes the impact of IFRS 16 Leases.
|
Ktes
|
Kilotonnes or 1,000 tonnes (metric).
|
Important notice
This announcement contains
'forward-looking statements' which includes all statements other
than statements of historical fact, including, without limitation,
those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations, or any
statements preceded by, followed by or that include the words
"targets", "believes", "expects", "aims", "intends", "will", "may",
"anticipates", "would, "could" or similar expressions or negatives
thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or
achievements of the Group to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are
based on numerous assumptions regarding the Group's present and
future business strategies and the environment in which the Group
will operate in the future. These forward-looking statements speak
only as at the date of this announcement. None of the Group or its
Affiliates undertakes or is under any duty to update this
announcement or to correct any inaccuracies in any such information
which may become apparent or to provide you with any additional
information, other than any requirements that the Group may have
under applicable law or the Listing Rules, the Prospectus Rules,
the Disclosure Guidance and Transparency Rules or MAR. To the
fullest extent permissible by law, such persons disclaim all and
any responsibility or liability, whether arising in tort, contract
or otherwise, which they might otherwise have in respect of this
announcement. The information in this announcement is subject to
change without notice.